US20060019261A1 - RNA-binding protein - Google Patents
RNA-binding protein Download PDFInfo
- Publication number
- US20060019261A1 US20060019261A1 US10/943,015 US94301504A US2006019261A1 US 20060019261 A1 US20060019261 A1 US 20060019261A1 US 94301504 A US94301504 A US 94301504A US 2006019261 A1 US2006019261 A1 US 2006019261A1
- Authority
- US
- United States
- Prior art keywords
- protein
- syncrip
- seq
- gene
- rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000044126 RNA-Binding Proteins Human genes 0.000 title claims abstract description 13
- 101710159080 Aconitate hydratase A Proteins 0.000 title claims description 8
- 101710159078 Aconitate hydratase B Proteins 0.000 title claims description 8
- 101710105008 RNA-binding protein Proteins 0.000 title claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 171
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 108
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 45
- 102000003137 synaptotagmin Human genes 0.000 claims abstract description 36
- 108060008004 synaptotagmin Proteins 0.000 claims abstract description 36
- 230000027455 binding Effects 0.000 claims abstract description 34
- 230000000694 effects Effects 0.000 claims abstract description 26
- 150000001413 amino acids Chemical class 0.000 claims abstract description 25
- 230000004570 RNA-binding Effects 0.000 claims abstract description 22
- 238000007792 addition Methods 0.000 claims abstract description 12
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims abstract description 10
- 238000012217 deletion Methods 0.000 claims abstract description 10
- 230000037430 deletion Effects 0.000 claims abstract description 10
- 238000006467 substitution reaction Methods 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims description 45
- 239000013598 vector Substances 0.000 claims description 36
- 239000003153 chemical reaction reagent Substances 0.000 claims description 15
- 239000002773 nucleotide Substances 0.000 claims description 15
- 125000003729 nucleotide group Chemical group 0.000 claims description 15
- 208000012902 Nervous system disease Diseases 0.000 claims description 11
- 208000025966 Neurological disease Diseases 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- 230000001105 regulatory effect Effects 0.000 claims description 10
- 102000005720 Glutathione transferase Human genes 0.000 claims description 9
- 108010070675 Glutathione transferase Proteins 0.000 claims description 9
- 229940124597 therapeutic agent Drugs 0.000 claims description 9
- 239000013592 cell lysate Substances 0.000 claims description 8
- 239000007795 chemical reaction product Substances 0.000 claims description 7
- 230000003955 neuronal function Effects 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 5
- 102000037865 fusion proteins Human genes 0.000 claims description 5
- 108020001507 fusion proteins Proteins 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 230000001413 cellular effect Effects 0.000 claims 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract description 7
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract description 7
- 108700020471 RNA-Binding Proteins Proteins 0.000 abstract description 2
- 101710141313 Heterogeneous nuclear ribonucleoprotein Q Proteins 0.000 description 140
- 102100028896 Heterogeneous nuclear ribonucleoprotein Q Human genes 0.000 description 139
- 235000018102 proteins Nutrition 0.000 description 87
- 210000004027 cell Anatomy 0.000 description 69
- 108020004414 DNA Proteins 0.000 description 30
- 241000699666 Mus <mouse, genus> Species 0.000 description 23
- 239000002299 complementary DNA Substances 0.000 description 23
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 20
- 239000003795 chemical substances by application Substances 0.000 description 20
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 17
- 239000012634 fragment Substances 0.000 description 17
- 230000014509 gene expression Effects 0.000 description 17
- 210000002504 synaptic vesicle Anatomy 0.000 description 16
- 238000001262 western blot Methods 0.000 description 16
- 102000001708 Protein Isoforms Human genes 0.000 description 15
- 108010029485 Protein Isoforms Proteins 0.000 description 15
- 210000001638 cerebellum Anatomy 0.000 description 14
- 239000002609 medium Substances 0.000 description 13
- 108091034057 RNA (poly(A)) Proteins 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 101001047853 Homo sapiens Heterogeneous nuclear ribonucleoprotein R Proteins 0.000 description 11
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 11
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 11
- 239000000427 antigen Substances 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- 238000002649 immunization Methods 0.000 description 11
- 230000003053 immunization Effects 0.000 description 11
- 244000005700 microbiome Species 0.000 description 11
- 235000002639 sodium chloride Nutrition 0.000 description 11
- 241000588724 Escherichia coli Species 0.000 description 10
- 102100023999 Heterogeneous nuclear ribonucleoprotein R Human genes 0.000 description 10
- 210000004408 hybridoma Anatomy 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- 239000002671 adjuvant Substances 0.000 description 9
- 238000007796 conventional method Methods 0.000 description 9
- 238000003752 polymerase chain reaction Methods 0.000 description 9
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 8
- 210000000628 antibody-producing cell Anatomy 0.000 description 8
- 210000004899 c-terminal region Anatomy 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 229920002684 Sepharose Polymers 0.000 description 7
- 108091092330 cytoplasmic RNA Proteins 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 230000036961 partial effect Effects 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 7
- 101710132383 66 kDa protein Proteins 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 description 6
- 210000004102 animal cell Anatomy 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 238000001415 gene therapy Methods 0.000 description 6
- 239000006166 lysate Substances 0.000 description 6
- 201000000050 myeloid neoplasm Diseases 0.000 description 6
- 230000003518 presynaptic effect Effects 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 241000238631 Hexapoda Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000004520 electroporation Methods 0.000 description 5
- 238000004255 ion exchange chromatography Methods 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 210000001589 microsome Anatomy 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 239000002858 neurotransmitter agent Substances 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000005194 fractionation Methods 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 239000012133 immunoprecipitate Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- CIPFCGZLFXVXBG-ZIQZFLOESA-N inositol 1,3,4,5-tetrakisphosphate Chemical compound O[C@H]1[C@H](OP(O)(O)=O)[C@@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O CIPFCGZLFXVXBG-ZIQZFLOESA-N 0.000 description 4
- 239000002052 molecular layer Substances 0.000 description 4
- 108010091212 pepstatin Proteins 0.000 description 4
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 4
- 210000000449 purkinje cell Anatomy 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000005062 synaptic transmission Effects 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 244000063299 Bacillus subtilis Species 0.000 description 3
- 235000014469 Bacillus subtilis Nutrition 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 229920000388 Polyphosphate Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 239000004098 Tetracycline Substances 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 3
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 3
- 235000011130 ammonium sulphate Nutrition 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 239000012148 binding buffer Substances 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 230000007910 cell fusion Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 210000000172 cytosol Anatomy 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 210000004565 granule cell Anatomy 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 3
- 108010052968 leupeptin Proteins 0.000 description 3
- 238000001638 lipofection Methods 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000001205 polyphosphate Substances 0.000 description 3
- 235000011176 polyphosphates Nutrition 0.000 description 3
- 230000007542 postnatal development Effects 0.000 description 3
- 108010092804 postsynaptic density proteins Proteins 0.000 description 3
- 210000000063 presynaptic terminal Anatomy 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 210000001768 subcellular fraction Anatomy 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000000946 synaptic effect Effects 0.000 description 3
- 229960002180 tetracycline Drugs 0.000 description 3
- 229930101283 tetracycline Natural products 0.000 description 3
- 235000019364 tetracycline Nutrition 0.000 description 3
- 150000003522 tetracyclines Chemical class 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- SXOUIMVOMIGLHO-AATRIKPKSA-N (E)-3-(indol-2-yl)acrylic acid Chemical compound C1=CC=C2NC(/C=C/C(=O)O)=CC2=C1 SXOUIMVOMIGLHO-AATRIKPKSA-N 0.000 description 2
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 102000002110 C2 domains Human genes 0.000 description 2
- 108050009459 C2 domains Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000701959 Escherichia virus Lambda Species 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 229960003896 aminopterin Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 239000008004 cell lysis buffer Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229960004198 guanidine Drugs 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- PLVPPLCLBIEYEA-UHFFFAOYSA-N indoleacrylic acid Natural products C1=CC=C2C(C=CC(=O)O)=CNC2=C1 PLVPPLCLBIEYEA-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 210000004897 n-terminal region Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 210000003538 post-synaptic density Anatomy 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- FGDZQCVHDSGLHJ-UHFFFAOYSA-M rubidium chloride Chemical compound [Cl-].[Rb+] FGDZQCVHDSGLHJ-UHFFFAOYSA-M 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- ZNJHFNUEQDVFCJ-UHFFFAOYSA-M sodium;2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid;hydroxide Chemical compound [OH-].[Na+].OCCN1CCN(CCS(O)(=O)=O)CC1 ZNJHFNUEQDVFCJ-UHFFFAOYSA-M 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000003568 synaptosome Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102100036826 Aldehyde oxidase Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- 101000975407 Caenorhabditis elegans Inositol 1,4,5-trisphosphate receptor itr-1 Proteins 0.000 description 1
- 101100298998 Caenorhabditis elegans pbs-3 gene Proteins 0.000 description 1
- 101100028791 Caenorhabditis elegans pbs-5 gene Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108700019745 Disks Large Homolog 4 Proteins 0.000 description 1
- 102000047174 Disks Large Homolog 4 Human genes 0.000 description 1
- 101000975393 Drosophila melanogaster Inositol 1,4,5-trisphosphate receptor Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241001452028 Escherichia coli DH1 Species 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 101150094690 GAL1 gene Proteins 0.000 description 1
- 101150038242 GAL10 gene Proteins 0.000 description 1
- 102100028501 Galanin peptides Human genes 0.000 description 1
- 102100024637 Galectin-10 Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 108010019372 Heterogeneous-Nuclear Ribonucleoproteins Proteins 0.000 description 1
- 102000006479 Heterogeneous-Nuclear Ribonucleoproteins Human genes 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 101000928314 Homo sapiens Aldehyde oxidase Proteins 0.000 description 1
- 101100121078 Homo sapiens GAL gene Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000007640 Inositol 1,4,5-Trisphosphate Receptors Human genes 0.000 description 1
- 108010032354 Inositol 1,4,5-Trisphosphate Receptors Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 108010053229 Lysyl endopeptidase Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589776 Pseudomonas putida Species 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 241000589180 Rhizobium Species 0.000 description 1
- 101150005863 SYNCRIP gene Proteins 0.000 description 1
- 241000589196 Sinorhizobium meliloti Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 108010057722 Synaptosomal-Associated Protein 25 Proteins 0.000 description 1
- 102000004183 Synaptosomal-Associated Protein 25 Human genes 0.000 description 1
- 108010090618 Syntaxin 1 Proteins 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102000004603 Vesicle-Associated Membrane Protein 1 Human genes 0.000 description 1
- 108010017743 Vesicle-Associated Membrane Protein 1 Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000002788 anti-peptide Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000000749 co-immunoprecipitation Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000007711 cytoplasmic localization Effects 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 101150069842 dlg4 gene Proteins 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 102000047703 human HNRNPR Human genes 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 208000009322 hypertrophic pyloric stenosis Diseases 0.000 description 1
- 239000000815 hypotonic solution Substances 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- 230000003957 neurotransmitter release Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 229940102127 rubidium chloride Drugs 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000012134 supernatant fraction Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000021966 synaptic vesicle transport Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- -1 vaseline Substances 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 230000028973 vesicle-mediated transport Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to a Synaptotagmin-binding and yet cytoplasmic RNA-binding protein and a gene encoding the protein.
- Synaptotagmin is a protein playing an important role in the transport of neurotransmitters and is known to be a family consisting of at least 12 isoforms (Syt-I to Syt-XII) in rat and mouse (Schiavo, G. et al. (1998) Biochem. Biophys. Res. Commun. 248, 1-8; Li, C. et al. (1995) Nature 375, 594-599).
- Syt-I is present on the synaptic vesicle membrane as an integral protein spanning the membrane once.
- This protein possesses two domains (termed C2A and C2B) homologous to the C2 regulatory region of protein kinase C (Sudhof, T. and Rizo, J. (1996) Neuron 17, 379-388; Schiavo, G. et al., (1998) Biochem. Biophys. Res. Commun. 248, 1-8).
- Syt-I is one of the proteins involved in neurotransmission and functions via the following mechanism.
- the C2B domain of Syt-I on synaptic vesicles fuses with the plasma membrane. (presynaptic membrane) to thereby open a fusion pore in the synaptic vesicle membrane. Then, neurotransmitters in the synaptic vesicle are transported through the pore.
- IP4 inositol 1,3,4,5-tetrakisphosphate
- the present inventor has analyzed those proteins capable of binding to Synaptotagmin and succeeded in isolating a protein which binds to Synaptotagmin and yet can bind to cytoplasmic RNA.
- the present invention has been achieved.
- the present invention relates to the following inventions:
- a recombinant protein selected from the group consisting of the following (a) and (b):
- a recombinant protein selected from the group consisting of the following (c) and (d):
- a gene comprising a DNA selected from the group consisting of the following (e) and (f):
- a recombinant vector comprising the gene.
- a transformant comprising the recombinant vector.
- a method of producing an RNA-binding protein comprising culturing the above transformant and recovering the RNA-binding protein from the resultant culture.
- a pharmaceutical composition for regulating neuronal functions comprising the protein as an active ingredient.
- a therapeutic agent for neurological diseases comprising the protein as an active ingredient.
- a reagent for detecting Synaptotagmin comprising the protein and/or an antibody against the protein.
- FIG. 1 shows cDNA clones of various lengths encoding the protein of the invention, SYNCRIP, (panel A) and the construction of truncated SYNCRIP genes (panel B).
- FIG. 2 shows an alignment between the amino acid sequence of SYNCRIP and the amino acid sequence of hnRNP R.
- FIG. 3 shows photographs indicating cytoplasmic localization of SYNCRIP.
- FIG. 4 shows the expression of SYNCRIP in subcellular fractions.
- FIG. 5 shows the expression of SYNCRIP during the postnatal development in mouse.
- FIG. 6 shows the expression pattern of SYNCRIP in mouse tissues.
- FIG. 7 shows the results of binding experiments between SYNCRIP and RNA molecules.
- FIG. 8 shows the results of reactivity experiments on antibodies against truncated SYNCRIP proteins (anti-A SYNCRIP antibodies).
- FIG. 9 shows the interaction of SYNCRIP with the C2A and/or C2B domain of Syt.
- FIG. 10 shows the interaction of a C-terminal region of SYNCRIP with the C2A or C2B domain of Syt.
- FIG. 11 shows the results of an immunohistochemical assay.
- the same cryosection was probed with anti-SYNCRIP-N antibody (panel A) and anti-Syt-I antibody (panel B).
- EGL external germinal layer
- ML molecular layer
- PL Purkinje cell layer
- IGL internal granule layer.
- FIG. 12 shows the interaction of SYNCRIP with Syt isoforms.
- FIG. 13 shows the interaction of SYNCRIP with Syt isoforms in cells.
- the protein of the invention is a Synaptotagmin-binding and yet cytoplasmic RNA-binding protein designated SYNCRIP (Synaptotagmin-binding, cytoplasmic RNA-interacting protein)(molecular weight: 66 kDa).
- SYNCRIP Synaptotagmin-binding, cytoplasmic RNA-interacting protein
- One region of SYNCRIP binds to cytoplasmic RNA (in particular, poly(A) region of mRNA) and another region of SYNCRIP binds to the C2B domain of Synaptotagmin on synaptic vesicles. Since synaptic vesicles are transported to the presynaptic terminal after their production in the neurosome, SYNCRIP functions as a “vehicle” for RNA.
- the binding of an inositol high polyphosphate to the C2B domain of Syt inhibits the fusion step of synaptic vesicles with the presynaptic membrane.
- the present inventor has analyzed those molecules which interact directly with the C2A and C2B domains of Syt. As a result, a protein which binds to Synaptotagmin and yet binds to cytoplasmic RNA has been found.
- the gene of the invention can be isolated by screening a cDNA library prepared from mRNA extracted from mouse or rat cerebellum using a DNA probe synthesized based on a partial amino acid sequence of SYNCRIP purified from cerebellum.
- mRNA The preparation of mRNA may be performed by conventional techniques. For example, cerebellum tissues or cells are treated with a guanidine reagent or phenol reagent to obtain total RNA. Then, poly(A + ) RNA (mRNA) is obtained therefrom by the affinity column method using oligo(dT)-cellulose or poly U-Sepharose using Sepharose 2B as a carrier, or by the batch method. Alternatively, poly(A + ) RNA fraction may be obtained by sucrose density-gradient centrifugation.
- a single-stranded cDNA is synthesized using oligo(dT) primers and a reverse transcriptase. Then, a double-stranded cDNA is synthesized from the single-stranded cDNA. The thus obtained double-stranded cDNA is integrated into an appropriate cloning vector to prepare a recombinant vector.
- a host such as E. coli is transformed with the recombinant vector. The resultant transformants are selected using tetracycline resistance and ampicillin resistance as indicators to thereby obtain a cDNA library.
- E. coli may be performed by conventional techniques.
- the method of Hanahan Hanahan, D. (1983) J. Mol. Biol. 166, 557-580
- a recombinant vector is added to competent cells prepared with calcium chloride, magnesium chloride or rubidium chloride
- the plasmid should contain drug resistance genes against tetracycline, ampicillin, etc.
- cloning vectors other than plasmid such as ⁇ phage may be used.
- a method may be used in which a pair of primers are synthesized based on a partial amino acid sequence of SYNCRIP purified from mouse cerebellum, and then a polymerase chain reaction (PCR) is performed using the primers.
- the purification of SYNCRIP from mouse cerebellum may be performed by suspending the cerebellum in an appropriate buffer, removing cell debris by centrifugation, incubating the homogenate with GST-Syt-II C2AB protein, eluting the bound proteins, separating the proteins by ion exchange chromatography and subjecting the resultant 66 kDa protein-rich fractions to SDS-PAGE.
- a cDNA synthesized from the mRNA by reverse transcription may be given.
- the primers may be designed based on amino acid sequence information on the purified SYNCRIP, taking into consideration of the expected size of the DNA fragment to be amplified and combinations of regenerate codons.
- the sense primer may be 5′-GTNACNGA(AG)GGN(TC)TNAC-3′ (SEQ ID NO: 8) based on a partial sequence VTEGLT (SEQ ID NO: 6); and the anti-sense primer may be 5′-(TC)TT(AG)TC(AG)TCNGG(TC)TG(AG)TG(AG)TA-3′ (SEQ ID NO: 9) based on a partial sequence YHQPDDK (SEQ ID NO: 7). It should be noted that primers which may be used in the PCR are not limited to these primers.
- the thus amplified DNA fragment is labeled with such as 32 P, 35 S or biotin, and hybridized as a probe with a nitrocellulose filter on which the DNA from the transformant has been denatured and immobilized.
- a nitrocellulose filter on which the DNA from the transformant has been denatured and immobilized.
- the nucleotide sequences of the thus obtained clones are determined.
- This sequencing may be performed by conventional techniques such as the chemical modification method of Maxam-Gilbert or the dideoxynucleotide chain termination method using M13 phage.
- sequencing is usually performed with an automated DNA sequencer (e.g., Perkin Elmer model 373A DNA Sequencer; BcaBEST Dideoxy Sequencing Kit (TAKARA)).
- an automated DNA sequencer e.g., Perkin Elmer model 373A DNA Sequencer; BcaBEST Dideoxy Sequencing Kit (TAKARA)
- the nucleotide sequence of the gene of the invention (full-length cDNA) is shown in SEQ ID NO: 3, and the amino acid sequence of the protein of the invention in SEQ ID NO: 4.
- an open reading frame is formed by a nucleotide sequence from position 154 to position 1836, which encodes the amino acid sequence of SEQ ID NO: 4. Therefore, in addition to the gene consisting of the nucleotide sequence of SEQ ID NO: 3, a gene consisting of the above mentioned nucleotide sequence of the open reading frame region is also included in the gene of the invention.
- amino acid sequence may have mutations such as deletion, substitution or addition of one or more of amino acids.
- RNA binding activity means an activity of a region of SYNCRIP to bind to cytoplasmic RNA (in particular, the poly(A) region of mRNA).
- Truncated versions of the protein having the amino acid sequence of SEQ ID NO: 4 are also included in the protein of the invention, as long as they have the RNA binding activity described above. Since a truncated SYNCRIP lacking amino acids 401-561 in SEQ ID NO: 4 (C-terminal truncated version) loses RNA binding activity, it can be said that the region of amino acids 401-561 possesses the RNA-binding activity and that the region of amino acids 1-400 does not have any effect on the RNA-binding activity of SYNCRIP.
- a protein having the amino acid sequence of the above-mentioned positions 401-561 (SEQ ID NO: 2) (i.e., the amino acid sequence of SEQ ID NO: 4 lacking amino acids 1-400) is also included in the protein of the invention, for example.
- a protein comprising the amino acid sequence as shown in SEQ ID NO: 4 may have mutations such as deletion, substitution of addition of one to several, preferably one to ten, and more preferably one to five amino acids within the region which does not have any effect on the RNA-binding activity (i.e., the region of amino acids 1-400 in SEQ ID NO: 4).
- the above-described truncated proteins which have mutation(s) in one or several amino acids are also included in the protein of the invention, as long as they have RNA binding activity.
- genes encoding proteins having the above-described mutation-introduced amino acid sequences, or genes encoding truncated SYNCRIP proteins or mutated versions thereof are also included in the gene of the invention as long as the proteins encoded by them have RNA binding activity.
- the protein of the invention is a protein which can also binds to Synaptotagmin.
- the target of binding may be any of the isoforms of Syt-I to -XI.
- the protein of the invention binds to Syt-I and -II.
- a DNA which can hybridize to the above-described gene of the invention under stringent conditions is also included in the gene of the invention.
- stringent conditions means, for example, sodium concentrations of 600-900 mM and temperatures of 60-68° C., preferably 65° C.
- a mutation into a gene may be performed by known techniques such as the method of Kunkel or the gapped duplex method, or by techniques based on these methods.
- a mutation may be introduced with a commercial mutagenesis kit using the site-specific mutagenesis technique (e.g., Mutant-K or Mutant-G; Takara) or LA PCR in vitro Mutagenesis Series kit (Takara).
- the gene of the invention can be obtained by chemical synthesis, by PCR using the cDNA of the gene as a template, or by hybridizing a DNA fragment having the nucleotide sequence of the gene as a probe.
- the recombinant vector of the invention can be obtained by ligating (inserting) the gene of the invention into an appropriate vector.
- the vector into which the gene of the invention is to be inserted is not particularly limited as long as it is replicable in a host.
- plasmid DNA, phage DNA or the like may be used.
- phage DNA which may be used in the invention include ⁇ phages (e.g., Charon4A, Charon21A, EMBL3, EMBL4, ⁇ gt10, ⁇ gt11 and ⁇ ZAP).
- an animal virus vector such as retrovirus or vaccinia virus; or an insect virus vector such as baculovirus may also be used.
- a method for insertion of the gene of the invention into a vector, a method may be employed in which the purified DNA is digested with an appropriate restriction enzyme and then inserted into the restriction site or multi-cloning site of an appropriate vector DNA for ligation.
- the gene of the invention must be operably linked to the vector.
- the vector of the invention may contain, if desired, cis elements such as an enhancer, a splicing signal, a poly(A) addition signal, selection markers, a ribosome binding sequence (SD sequence) or the like in addition to a promoter and the gene of the invention.
- selection marker dihydrofolate reductase gene, ampicillin resistance gene, neomycin resistance gene, or the like may be enumerated.
- the transformant of the invention may be obtained by introducing the recombinant vector of the invention into a host so that the gene of interest can be expressed.
- the host is not particularly limited as long as it can express the DNA of the invention.
- Specific examples of hosts which may be used in the invention include Escherichia bacteria such as E. coli; Bacillus bacteria such as Bacillus subtilis; Pseudomonas bacteria such as Pseudomonas putida; and Rhizobium bacteria such as Rhizobium meliloti.
- yeasts such as Saccharomyces cerevisiae, Schizosaccharomyces pombe ; animal cells such as COS cells, CHO cells; and insect cells such as Sf9 cells, Sf21 cells may be used.
- the recombinant vector of the invention is preferably not only capable of autonomous replication in the host but also composed of a promoter, a ribosome binding sequence, the gene of the invention and a transcription termination sequence.
- the vector may also contain a gene that controls the promoter.
- E. coli strains which may be used in the invention include E. coli K12 and DH1.
- Bacillus bacteria which may be used in the invention include Bacillus subtilis strains.
- any promoter may be used as long as it can direct the expression of the gene of the invention in a host such as E. coli .
- an E. coli - or phage-derived promoter such as trp promoter, lac promoter, P L promoter or P R promoter may be used.
- an artificially altered promoter such as tac promoter may also be used.
- any method for introducing the recombinant vector into a bacterium any method of DNA transfer into bacteria may be used. For example, a method using calcium ions (Cohen, S. N. et al., Proc. Natl. Acad. Sci., USA, 69:2110-2114 (1972)) or electroporation may be used.
- yeast When yeast is used as the host, Saccharomyces cerevisiae, Schizosaccharomyces pombe or Pichia pastoris may be used, for example.
- a promoter which may be used in this case is not particularly limited. Any promoter may be used as long as it can direct the expression of the gene of the invention in yeast.
- GAL1 promoter, GAL10 promoter, heat shock protein promoter, MF ⁇ 1 promoter, PH05 promoter, PGK promoter, GAP promoter, ADH promoter, or AOX1 promoter may be enumerated.
- any method of introducing the recombinant vector into yeast any method of DNA transfer into yeast may be used. For example, electroporation (Becker, D. M.,.
- simian COS-7 or Vero cells Chinese hamster ovary cells (CHO cells), mouse L cells, rat GH3 cells, human FL cells; or the like may be used.
- CHO cells Chinese hamster ovary cells
- mouse L cells mouse L cells
- rat GH3 cells human FL cells
- human FL cells or the like
- SR ⁇ promoter SV40 promoter
- LTR promoter LTR promoter
- CMV promoter CMV promoter
- the early gene promoter of human cytomegalovirus may also be used.
- electroporation, the calcium phosphate method, or lipofection may be used, for example.
- Sf9 cells When an insect cell is used as the host, Sf9 cells, Sf21 cells or the like may be used.
- a method for introducing the recombinant vector into an insect cell the calcium phosphate method, lipofection, or electroporation may be used, for example.
- the protein of the invention can be obtained by culturing the above-described transformant and recovering the protein from the resultant culture.
- culture means any of the following materials: culture supernatant, cultured cells or microorganisms, or disrupted products from cultured cells or microorganisms.
- the cultivation of the transformant of the invention is carried out in accordance with conventional methods commonly used for culturing hosts.
- either a natural or synthetic medium may be used as long as it contains carbon sources, nitrogen sources and inorganic salts assimilable by the microorganism and is capable of effective cultivation of the transformant.
- carbon sources carbohydrates such as glucose, fructose, sucrose, starch; organic acids such as acetic acid, propionic acid; and alcohols such as ethanol and propanol may be used.
- ammonia As nitrogen sources, ammonia; ammonium salts of inorganic or organic acids such as ammonium chloride, ammonium sulfate, ammonium acetate, ammonium phosphate; other nitrogen-containing compounds; Peptone; meat extract; corn steep liquor and the like may be used.
- inorganic substances potassium dihydrogen phosphate, dipotassium hydrogen phosphate, magnesium phosphate, magnesium sulfate, sodium chloride, iron(II) sulfate, manganese sulfate, copper sulfate, calcium carbonate and the like may be used.
- the cultivation is carried out under aerobic conditions (such as shaking culture or aeration agitation culture) at 37° C. for 6 to 24 hrs.
- the pH is maintained at 7.0 to 7.5.
- the pH adjustment is carried out using an inorganic or organic acid, or an alkali solution or the like.
- an antibiotic such as ampicillin or tetracycline may be added to the medium if necessary.
- an inducer may be added to the medium if necessary.
- an inducer may be added to the medium if necessary.
- IPTG isopropyl- ⁇ -D-thiogalactopyranoside
- IAA indoleacrylic acid
- a medium to culture a transformant obtained from an animal cell as a host commonly used RPMI1640 medium or DMEM medium, or one of these media supplemented with fetal bovine serum, etc. may be used. Usually, the cultivation is carried out in the presence 5% CO 2 at 37° C. for 1 to 30 days. During the cultivation, antibiotics such as kanamycin or penicillin may be added to the medium if necessary.
- SYNCRIP protein of the invention is recovered by disrupting the microorganisms or cells, if the protein is produced within the microorganisms or cells. If SYNCRIP protein of the invention is produced outside the microorganisms or cells, the culture fluid is used as it is or subjected to centrifugation to remove the microorganisms or cells. Thereafter, the resultant supernatant is subjected to conventional biochemical techniques used for isolating/purifying proteins. These techniques include ammonium sulfate precipitation, gel chromatography, ion exchange chromatography and affinity chromatography, and may be used independently or in an appropriate combination. Thus, SYNCRIP protein of the invention can be isolated and purified from the above-mentioned culture.
- antibodies against SYNCRIP may be prepared using the SYNCRIP isolated and purified as described above or a fragment thereof as an antigen.
- Animals are immunized with the antigen prepared as described above. If the animal is rabbit, the dose of the antigen is 100-500 ⁇ g/rabbit when an adjuvant is used.
- adjuvants useful in the present invention include Freund's complete adjuvant (FCA), Freund's incomplete adjuvant (FIA) and aluminium hydroxide adjuvant.
- Immunization is carried out by administering the antigen to a mammal (e.g., rat, mouse or rabbit).
- the antigen is administered intravenously, subcutaneously or intraperitoneally.
- the interval of immunization is not particularly limited. Immunization is carried out 1 to 10 times, preferably 2 to 3 times, at intervals of several days to several weeks, preferably 2 to 3 weeks.
- Antibody titer is determined daily from day 6 to day 60 after the final immunization. When the maximum antibody titer is shown, blood is taken from the animal to thereby obtain an anti-serum.
- the determination of antibody titer may be performed by ELISA (enzyme-linked immunosorbent assay), RIA (radioimmunoassay) or the like.
- purification may be performed by conventional methods such as ammonium sulfate salting out, ion exchange chromatography, gel filtration or affinity chromatography. These methods may be used independently or in combination.
- an adjuvant (commercial Freund's complete adjuvant, Freund's incomplete adjuvant, etc.) may be mixed with the antigen for efficient immunization.
- Immunization is carried out by administering the antigen to a mammal (e.g., rat, mouse or rabbit). If the animal is mouse, the dose of the antigen per administration is 50 ⁇ g/mouse. In principle, the antigen is administered intravenously, subcutaneously or intraperitoneally. The interval of immunization is not particularly limited. Immunization is carried out at least 2 to 3 times at intervals of several days to several weeks, preferably 2 to 3 weeks. After the final immunization, antibdy-producing cells are recovered. Examples of antibody-producing cells include spleen cells, lymph node cells and peripheral blood cells. Among all, spleen cells are preferable.
- myeloma cells In order to obtain hybridomas, antibody-producing cells and myeloma cells are fused.
- myeloma cells to be fused with antibody-producing cells a commonly available cell strain derived from an animal such as mouse may be used.
- Preferable cell strains are those which have drug selectivity and cannot survive in HAT selection medium (containing hypoxanthine, aminopterin and thymidine) when unfused, but can survive therein only when fused with antibody-producing cells.
- HAT selection medium containing hypoxanthine, aminopterin and thymidine
- myeloma cells useful in the present invention include mouse myeloma cell strains P3X63-Ag.8.U1 (P3U1), P3/NSI/1-Ag4-1 and Sp2/0-Ag14.
- Cell fusion between the above-described myeloma cells and antibody-producing cells is performed as follows. Briefly, the antibody-producing cells and myeloma cells are mixed at a ratio between 15:1 and 25:1 in an animal cell culture medium such as serum-free DMEM or RPMI-1640. Then, fusion reaction is performed in the presence of a cell fusion promoter such as polyethylene glycol, or by electric pulse treatment (e.g., electroporation).
- a cell fusion promoter such as polyethylene glycol
- electric pulse treatment e.g., electroporation
- Hybridomas of interest are selected from fused cells.
- fused cells are cultured in a medium containing hypoxanthine, aminopterin and thymidine. Then, cells growing therein are obtained as hybridomas.
- culture supernatants of grown hybridomas are screened for the presence of antibodies of interest.
- the screening of hybridomas may be performed by any of the conventional methods. For example, a part of the culture supernatant contained in a well in which a hybridoma is growing may be taken and screened by ELISA, RIA or the like.
- the cloning of fused cells is performed by, for example, the limiting dilution method.
- hybridomas which are monoclonal antibody-producing cells are established.
- the recovery of monoclonal antibodies from the established hybridomas may be performed by conventional cell culturing methods. Briefly, the hybridomas are cultured in an animal cell culture medium (such as 10% fetal bovine serum-containing RPMI-1640 or MEM medium) under conventional culture conditions (e.g., at 37° C., under 5% CO 2 ) for 3 to 10 days. Then, antibodies are recovered from culture supernatants.
- an animal cell culture medium such as 10% fetal bovine serum-containing RPMI-1640 or MEM medium
- conventional culture conditions e.g., at 37° C., under 5% CO 2
- the antibodies may be purified, if necessary, by conventional methods such as ammonium sulfate fractionation, ion exchange chromatography, affinity chromatography and gel chromatography. These methods may be used independently or in combination.
- the protein of the invention can bind to both RNA and Synaptotagmin, and Synaptotagmin moves from the neurosome to the nerve terminal. Therefore, the protein of the invention performs a function of transporting RNA molecules encoding neurotransmitters to the nerve terminal. Accordingly, the gene or the protein of the invention may be used as a regulator for allowing the expression of neurotransmitters at the nerve terminal, i.e., as a pharmaceutical for regulating neuronal functions.
- the gene or the protein of the invention is useful as an activator for neurons or an agent for gene therapy for neurological diseases.
- the therapeutic agent or agent for gene therapy of the invention can be administered orally or parenterally and systemically or locally.
- the target of use is not particularly limited.
- the agent of the invention may be used for a specific purpose of treating or preventing neurological diseases such as Parkinson's disease and Alzheimer's disease which develop when neurotransmission does not function or is decreased.
- neurological diseases such as Parkinson's disease and Alzheimer's disease which develop when neurotransmission does not function or is decreased.
- Such a disease may be an independent disease, or may be complicated with other neurological disease, or may be complicated with even a disease other than neurological diseases; in any case, such a disease may be the target of use of the protein or gene of the invention.
- the regulator When the regulator of the invention is administered orally, the regulator may be prepared into any of the formulations such as tablets, capsules, granules, powder, pills, troches, internal liquid agents, suspensions, emulsions or syrups. Alternatively, the regulator may be prepared into a dry product which is re-dissolved just before use.
- the regulator of the invention When the regulator of the invention is administered parenterally, the regulator may be formulated into intravenous injections (including drops), intramuscular injections, intraperitoneal injections, subcutaneous injections, suppositories, or the like. Injections are supplied in the form of unit dosage ampules or multi-dosage containers.
- formulations may be prepared by conventional methods using appropriate excipients, fillers, binders, wetting agents, disintegrating agents, lubricating agents, surfactants, dispersants, buffers, preservatives, dissolution aids, antiseptics, flavoring/perfuming agents, analgesics, stabilizers, isotonic agents, etc. conventionally used in pharmaceutical preparations.
- Each of the above-described formulations may contain pharmaceutically acceptable carriers or additives.
- pharmaceutically acceptable carriers or additives include water, pharmaceutically acceptable organic solvents, collagen, polyvinyl alcohol, polyvinyl pyrrolidone, carboxyvinyl polymers, sodium alginate, water-soluble dextran, sodium carboxymethyl starch, pectin, xanthan gum, gum arabic, casein, gelatin, agar, glycerol, propylene glycol, polyethylene glycol, vaseline, paraffin, stearyl alcohol, stearic acid, human serum albumin, mannitol, sorbitol and lactose.
- these additives are selected or combined appropriately depending of the form of the preparation.
- the dosage levels of the therapeutic agent of the invention will vary depending on such factors as the age of the subject, the route of administration and the number of times of administration, and may be varied in a wide range.
- an effective amount of the protein of the invention When an effective amount of the protein of the invention is administered in combination with an appropriate diluent and a pharmaceutically acceptable carrier, the effective amount of the protein may be in the range from 0.01 to 1000 mg/kg body weight per administration.
- the therapeutic agent may be administered once a day or in several dosages per day.
- the gene of the invention When the gene of the invention is used as an agent for gene therapy to treat neurological diseases, the gene of the invention may be directly administered by injection, or a vector incorporating the gene of the invention may be administered.
- a suitable vector for this purpose include an adenovirus vector, adeno-associated virus vector, herpes virus vector, vaccinia virus vector and retrovirus vector.
- the gene of the invention can be administered efficiently.
- the gene of the invention may be enclosed in phospholipid vesicles such as liposomes, and the resultant liposomes may be administered to the subject.
- liposomes are closed vesicles containing a biodegradable material
- the gene of the invention and liposomes are mixed so that the gene is retained in the internal aqueous layer and lipid bilayer of the liposomes (a liposome-gene complex is formed).
- the gene in the complex is taken into the cells (lipofection). Then, the resultant cells may be administered by the methods as described below.
- local administration to the central nervous system may be performed in addition to conventional systemic administration such as intravenous or intra-arterial administration.
- conventional systemic administration such as intravenous or intra-arterial administration.
- an administration method combined with catheter techniques or surgical operations may also be employed.
- the dosage levels of the agent for gene therapy of the invention vary depending on such factors as the age, sex and conditions of the subject, the route of administration, the number of times of administration, and the type of the formulation. Usually, it is appropriate to administer the gene of the invention in an amount of 0.1-100 mg/adult body per day.
- the antibody of the invention reacts with SYNCRIP or a fragment thereof, the antibody may be used as a reagent for detecting SYNCRIP.
- the method of detection of SYNCRIP is not particularly limited. For example, Western blotting may be employed.
- a test sample e.g., cell component or subcellular fraction
- the antibody of the invention which has been labeled (e.g., radioactively or fluorescently) in advance, followed by detection of signals.
- the antibody used for the detection of SYNCRIP may be either an antibody against a protein having the full-length amino acid sequence of SYNCRIP or an antibody against a peptide having a partial amino acid sequence of SYNCRIP.
- Synaptotagmin contains C2A and C2B domains, and SYNCRIP binds to the C2B domain.
- the C2B domain of Synaptotagmin can be the target of detection.
- the detection of Synaptotagmin may be performed by reacting a test sample (cell lysate) with SYNCRIP or a fragment thereof and subjecting the reaction product to Western blotting.
- a cell lysate or subcellular fraction containing Synaptotagmin is fractionated by electrophoresis and then reacted with SYNCRIP or a fragment thereof pre-labeled radioactively or fluorescently, followed by detection of signals.
- a fusion protein between Synaptotagmin and GST is prepared by conventional methods and then reacted with SYNCRIP.
- the reaction product is recovered with glutathione-Sepharose and subjected to Western blotting to detect signals.
- a labeled antibody against SYNCRIP or a fragment thereof is used to determine signals generated by the antibody.
- the antibody may also be used as a reagent for detecting Synaptotagmin.
- SYNCRIP was partially purified as previously described (Mizutani, A. et al. (1997) Biochem Biophys. Res. Commun. 240, 128-131) with some improvement.
- Triton X-100 was added to give a supernatant fraction (S1) with a final concentration of 1% (w/v).
- This fraction (S1) was left on ice for 30 min, and then ultracentrifuged at 16,000 ⁇ g for 30 min to obtain a soluble fraction, which was incubated with purified GST-Syt-II C2AB protein (5 mg) at 4° C. for 4 hr.
- 1 ml (50% slurry) of glutathione-Sepharose was added and incubated at 4° C. for 1 hr.
- a 66 kDa protein was eluted at around 0.2 M NaCl, pH 8.0. Fractions rich in the 66 kDa protein were subjected to 10% SDS-polyacrylamide gel electrophoresis followed by staining with Coomassie Brilliant Blue R. The 66 kDa protein band was cut out from the gel and digested with lysylendopeptidase (Wako Purechemical) as described previously (Rosenfeld, J. et al. (1992) Annal. Biochem. 203, 173-179).
- VTEGLTDVILYHQPDDK A pair of degenerate primers corresponding to partially digested peptide 1 (VTEGLTDVILYHQPDDK; SEQ ID NO: 5) were synthesized.
- Sense primer was based on the sequence VTEGLT (SEQ ID NO: 6)
- anti-sense primer was based on the sequence YHQPDDK (SEQ ID NO: 7).
- PCR was performed for 35 cycles (at 94° C. for 30 sec, at 55° C. for 1 min and at 72° C. for 1 min) using a random-primed, mouse cerebellum-derived first strand cDNA as a template and a Takara PCR kit.
- the resultant 51 bp PCR product was cloned into pT7Blue (Novagen) followed by confirmation of the sequence thereof.
- This 51 bp fragment was labeled with [ ⁇ - 32 P] dCTP (Amersham Pharmacia Biotech) and used as a probe for screening about 5.0 ⁇ 10 5 plaques from a mouse cerebellum-derived cDNA library.
- Partial amino acid sequences of the 66 kDa protein were determined as described above, and cDNAs were isolated based on the amino acid sequences determined. As a result, several clones partially overlapping were obtained ( FIG. 1A ).
- a 5′- or 3′-end fragment (about 200 bp) of clone 1a ( FIG. 1 ) as a hybridization probe a ⁇ gt cDNA library was screened to thereby obtain a cDNA encoding the full-length SYNCRIP.
- the cloned cDNA was subcloned into pBluescript and sequenced in both directions by the dideoxy chain termination method (BcaBEST Dideoxy Sequencing Kit; Takara).
- the nucleotide sequence of the gene (cDNA) encoding the full-length SYNCRIP is shown in SEQ ID NO: 3.
- the amino acid sequence of SYNCRIP (open reading frame) is shown in SEQ ID NO: 4.
- hnRNP R human heterogeneous nuclear ribonucleoprotein R
- FIG. 2 The homology analysis of the deduced amino acid sequence of the cloned cDNA revealed that this amino acid sequence is highly homologous to human heterogeneous nuclear ribonucleoprotein R (hnRNP R) ( FIG. 2 ).
- hnRNP R is a 82 kDa protein defined by Hassefeld et al. (Hassefeld, W. et al. (1998) Nucleic Acids Res. 26, 439-445). This protein is known to be localized in the nucleoplasm and, as described later, is completely different from SYNCRIP of the invention in terms of function.
- both SYNCRIP and hnRNP R were expressed in COS-7 cells and their behaviors were examined in order to confirm the region of expression of SYNCRIP within cells as well as to demonstrate that SYNCRIP and hnRNP R are functionally different substances. The procedures were as described below.
- SYNCRIP-N antibody an N-terminal region of SYNCRIP (the boxed region in FIG. 2 ) and designated anti-SYNCRIP-N antibody.
- the other is against a region with complete homology between SYNCRIP and hnRNP R (the double underlined region in FIG. 2 ) and designated anti-SYNCRIP-Pep antibody.
- a (His) 6 -tagged recombinant protein comprising the N-terminal region of SYNCRIP (amino acids 1-170) was expressed in E. coli and partially purified with ProBond resin (Invitrogen). Then, the protein was fully purified by MonoQ column chromatography. Three hundred micrograms of the purified protein was administered to Japan White rabbits together with Freund's complete adjuvant for immunization (subcutaneous injection, at intervals of 14 days). On the other hand, a GST fusion protein containing a region corresponding to the above antigenic protein was covalently bound to a carrier and packed in a column to thereby prepare an affinity column. Blood was collected from the rabbit to obtain a serum, which was then applied to the affinity column to purify anti-SYNCRIP-N antibody.
- An antibody against a peptide having amino acids 140-152 of SYNCRIP was prepared from rabbits using this peptide (to which a Cys residue was artificially introduced at its N-terminus) crosslinked with keyhole limpet hemocyanin.
- the anti-peptide antibody i.e., anti-SYNCRYP-Pep antibody
- panel A is a photograph showing the behavior of SYNCRIP over-expressed in COS-7 cells by the indirect immunofluorescence technique using anti-SYNCRIP-N antibody stained.
- Panel B is a photograph showing the behavior of SYNCRIP over-expressed in COS-7 cells by indirect immunofluorescence technique using anti SYNCRIP-Pep antibody.
- mouse cerebellum was fractionated into a crude nuclear fraction, cytosol fraction, crude microsome fraction and crude synaptic vesicle fraction. Then, the localization of SYNCRIP in each of these fractions was examined. The results are shown in FIG. 4 .
- P1 is a crude nuclear fraction from mouse cerebellum; S3 is a supernatant (cytosol) from nuclear fractionation; P3 is a crude microsome fraction containing vesicles; and P2′ is a crude synaptosome fraction.
- LP1 is a synaptic heavy membrane fraction obtained from synaptosomes lysed in a hypotonic solution; LP2 is a synaptic vesicle fraction; LS2 is a synaptic cytosol fraction; and PSD is a postsynaptic density fraction prepared from LP1 fraction.
- the bands of IP3R Type I indicate inositol 1,4,5 triphosphate receptor I, and serve as a marker for crude microsome fraction. Further, the bands of PSD95 indicate postsynaptic density proteins, and serve as a marker for postsynaptic density fraction.
- the time of expression of SYNCRIP was determined by preparing cerebellum homogenates from postnatal day 0, 3, 7, 12, 15 and 21 mice and adult mice, and performing Western blotting using anti-SYNCRIP-N antibody.
- the expression of Syt-I contained in each of the homogenate was also determined. The results are shown in FIG. 5 .
- the bands in the upper panel indicate SYNCRIP, and the bands in the lower panel Syt-I.
- tissues expressing SYNCRIP were determined by preparing homogenates (30 ⁇ g for each) from individual tissues of postnatal day 7 mice and performing Western blotting using anti-SYNCRIP-Pep antibody. The expression of hnRNP R in individual tissues was also determined. The results are shown in FIG. 6 . In FIG. 6 , the bands pointed out by the upper arrow indicate hnRNP R (82 kDa), and the bands pointed out by the lower arrow SYNCRIP (66 kDa).
- [ 35 S]-labeled SYNCRIP was prepared by in vitro translation using a TNT-coupled reticulocyte lysate system (Promega). An aliquot of [ 35 S]-labeled SYNCRIP was incubated with an indicated amount of poly(A), poly(C) or poly(U) RNA or yeast tRNA in 50 ⁇ l of a binding buffer (10 mM Tris-HCl (pH 8.0), 1 mM EDTA and 10 mM NaCl) at 25° C. for 30 min. Then, 50 ⁇ l of poly(U)-Sephadex (20% slurry in the binding buffer) was added to each of the mixtures followed by incubation at 25° C. for 45 min. After washing the beads with 500 ⁇ l of the binding buffer 4 times, the bound fractions were subjected to 10% SDS-PAGE and analyzed by autoradiography.
- a binding buffer (10 mM Tris-HCl (pH 8.0), 1 mM EDTA
- [ 35 S]-labeled SYNCRIP indeed bound to poly(U) RNA Sephadex.
- poly(A) RNA is not contained in the sample (i.e., poly(A): 0)
- a strong band appears.
- the band becomes weaker because the binding of the labeled SYNCRIP to the poly(U) RNA on carrier beads is inhibited, which results in liberation of SYNCRIP and its binding to poly(A) RNA ( FIG. 7 ; the three lanes under poly(A) ).
- no changes in the intensity of bands were observed in yeast tRNA and poly(C) RNA. These substances did not compete with the poly(U) RNA on carrier beads for SYNCRIP binding.
- the protein of the invention, SYNCRIP binds preferentially to poly(A) RNA.
- a cell lysate was prepared from each of the COS-7 cells expressing individual SYNCRIP proteins by suspending the cells in a cell lysis buffer of the following composition. Then, the cell lysate was centrifuged at 12,000 rpm at 4° C. for 20 min.
- Cell lysis buffer 10 mM Hepes-NaOH (pH 7.4), 100 mM NaCl, 1 mM ⁇ -mercaptoethanol, 1 mM EDTA, 1% NP-40, 0.2 mM PMSF, 10 ⁇ M leupeptin, and 10 ⁇ M pepstatin A.
- Each lysate was incubated with an equal amount of GST-Sty-II C2B protein at 4° C. for 2 hr. Then, GST-Sty-II C2B protein-bound fractions were recovered with glutathione-Sepharose and examined by Western blotting using anti-SYNCRIP-Pep antibody.
- the antibody used in the Western blotting was prepared in Example 2. (In the subsequent Western blotting analyses, the antibodies used were also from Example 2.)
- Mouse whole brain detergent-extracts (2.5 mg/ml) were prepared in a lysis buffer of the following composition.
- Lysis buffer 10 mM Hepes-NaOH (pH 7.4), 140 mM NaCl, 1% (w/v) Triton X-100, 1 mM ⁇ -mercaptoethanol, 1 mM EDTA, 0.2 mM PMSF, 10 ⁇ M leupeptin and 10 ⁇ M pepstatin A.
- SYNCRIP for the expression of SYNCRIP in an insect cell Sf9, a cDNA fragment encoding full-length SYNCRIP was subcloned into pFASTBAC1 (Life Technology) to create a recombinant bacurovirus carrying SYNCRIP, which was then proliferated in accordance with the manufacturer's instructions.
- Sf9 cells cultured in TNM-FH medium supplemented with 10% fetal calf serum were infected with the proliferated recombinant virus. Forty-eight hours after the infection, the cells were used in binding experiments.
- a cell lysate containing the full-length SYNCRIP expressed in Sf9 cells was prepared in the same manner as described in (1) above. Each aliquot was incubated with 10-20 ⁇ g of one of GST fusion proteins with C2B domains from various Syts. The bound proteins were recovered and subjected to Western blotting using anti-SYNCRIP-N antibody to examine the binding of SYNCRIP to C2B domains from various Syts.
- a His 6 -tagged recombinant protein comprising a C-terminal region of SYNCRIP (amino acids 401-561) was expressed in E. coli using pREST plasmid (Invitrogen).
- the recombinant protein was recovered from inclusion bodies by using a denaturing solution (6 M guanidine-HCl, 10 mM Tris-HCl (pH 8.0), 0.5 M NaCl, 1 mM ⁇ -mercapto-ethanol) and purified with ProBond resin.
- the denatured recombinant protein was refolded by dialysis against 10 mM Tris-HCl (pH 8.0), 10 mM ⁇ -mercaptoethanol, 0.1 M NaCl and 1 mM EDTA, with gradual decrease of urea concentration from 6 M to 0.001 M.
- the dialysate was centrifuged at 12,000 rpm at 4° C. for 20 min to remove the malfolded part and insoluble matter. After aliquots were incubated with various GST-fusion proteins with one of the Syt-II C2 domains, bound proteins were recovered and subjected to Western blotting using anti-Xpress antibody (Invitrogen).
- DNA fragments encoding Syt isoforms tagged with T7-epitope at the N-terminus were transiently transfected into COS cells separately. Forty-eight hours after the transfection, cells were harvested and suspended in a suspension buffer (10 mM Hepes-NaOH (pH 7.4), 100 mM NaCl, 0.5 mM ⁇ -mercaptoethanol, 1 mM EDTA, 1% NP-40, 0.2 mM PMSF, 10 ⁇ M leupeptin and 10 g M pepstatin).
- a suspension buffer (10 mM Hepes-NaOH (pH 7.4), 100 mM NaCl, 0.5 mM ⁇ -mercaptoethanol, 1 mM EDTA, 1% NP-40, 0.2 mM PMSF, 10 ⁇ M leupeptin and 10 g M pepstatin).
- Lysates were prepared by centrifugation of the cell suspension at 12,000 rpm for 20 min and incubated with affinity purified anti-SYNCRIP-N antibody (3.5 ⁇ g antibody/1 ml lysate) at 4° C. for 2 hr, followed by another incubation with 10 ⁇ l (50% slurry) of protein G-Sepharose (Amersham Pharmacia Biotech) at 4° C. for 1 hr. After washing the beads with the suspension buffer 5 times, the resultant immunoprecipitates were subjected to Western blotting to examine the binding of SYNCRIP to T7-tagged Syt isoforms.
- a DNA fragment encoding SYNCRIP was transfected into COS-7 cells. Forty-eight hours after the transfection, the cells were washed with PBS twice and fixed with 4% paraformaldehyde in PBS at room temperature for 20 min. Fixed cells were permeabilized with 0.1% Triton X-100 in PBS for 5 min and immediately washed with PBS 3 times. After blocking with 2% normal goat serum in PBS, cells were incubated with anti-SYNCRIP-N antibody (0.27 ⁇ g/ml) or anti-SYNCRIP-Pep antibody (0.55 ⁇ g/ml) in the blocking buffer at room temperature for 1 hr.
- SYNCRIP was expressed in most neurons, i.e. granule cells in both external germinal layer and internal granular layer, and Purkinje cells ( FIG. 11 ).
- LP2 fraction that is a representative synaptic vesicle-rich fraction morphologically ( FIG. 4 ).
- anti-SYNCRIP-N antibody-reactive signals concentrated in perinuclear and somatic regions of granule cells and Purkinje cells, and were almost absent in the molecular layer without migrating granule cells therein ( FIG. 11A , the region indicated as “ML”).
- SYNCRIPT is expressed in every step of neurodevelopment and expressed ubiquitously in a wide variety of tissues, it is believed that the targets of SYNCRIP are not only the major Syt isoforms (Syt-I and Syt-II), but also other Syt isoforms. Then, the present inventor performed binding experiments between SYNCRIP and 11 Syt isoforms.
- SYNCRIP was expressed in Sf9 cells (see Section (3) of Example 4). After preparation of a lysate from the cells, each aliquot was incubated with an almost equal volume of GST-Syt-C2B. The binding of SYNCRIP to GST-Syt-C2B was detected by immunoprecipitation using anti-SYNCRIP-N antibody.
- T7-epitope-tagged full-length Syt-IV, -V, -VII, -VIII and -IX were transiently expressed in COS-7 cells. Lysates were prepared from COS-7 cells and immunoprecipitated with anti-SYNCRIP-N antibody. The immunoprecipitates were examined by Western blotting with both anti-SYNCRIP-N antibody ( FIG. 13 ; middle panel) and anti-T7 antibody ( FIG. 13 ; lower panel). The detection of T7-tagged Syt isoforms (Syt-IV, -VII, -VIII and -IX) by Western blotting with anti-T7 antibody confirmed that they were expressed at almost equal levels ( FIG. 13 ; upper panel).
- RNA-binding proteins are provided. Since the protein of the invention is able to bind to Synaptotagmin on synaptic vesicles, the protein is useful as an agent for regulating neurotransmission.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention provides Synaptotagmin-binding and yet RNA-binding proteins and genes encoding the proteins. The invention relates to a recombinant protein selected from the group consisting of the following (a) and (b), as well as a gene encoding the protein: (a) a protein comprising the amino acid sequence as shown in SEQ ID NO: 2 (b) a protein which comprises the amino acid sequence as shown in SEQ ID NO: 2 having deletion, substitution or addition of one or several amino acids and which has RNA binding activity.
Description
- 1. Field of the Invention
- The present invention relates to a Synaptotagmin-binding and yet cytoplasmic RNA-binding protein and a gene encoding the protein.
- 2. Description of the Prior Art
- It is known that the release of neurotransmitters from the presynaptic terminal in mammals begins with the fusion of synaptic vesicles with the axon-terminal plasma membrane. The synaptic vesicle protein VAMP1 or 2 and the two presynaptic membrane proteins Syntaxin 1 and SNAP-25 are essential for neurotransmitter release (Scheller, R. H. (1995) Neuron 14, 893-897; Sudhof, T. C. (1995) Nature 375, 645-653; Augustine, G. J. et al. (1996) Annu. Rev. Pharmacol. Toxioccol. 36, 659-701). The formation of a complex among these proteins is the first molecular process for the synaptic vesicle fusion with the above-mentioned plasma membrane.
- On the other hand, Synaptotagmin (Syt) is a protein playing an important role in the transport of neurotransmitters and is known to be a family consisting of at least 12 isoforms (Syt-I to Syt-XII) in rat and mouse (Schiavo, G. et al. (1998) Biochem. Biophys. Res. Commun. 248, 1-8; Li, C. et al. (1995) Nature 375, 594-599). Among these isoforms, Syt-I is present on the synaptic vesicle membrane as an integral protein spanning the membrane once. This protein possesses two domains (termed C2A and C2B) homologous to the C2 regulatory region of protein kinase C (Sudhof, T. and Rizo, J. (1996) Neuron 17, 379-388; Schiavo, G. et al., (1998) Biochem. Biophys. Res. Commun. 248, 1-8). Syt-I is one of the proteins involved in neurotransmission and functions via the following mechanism. The C2B domain of Syt-I on synaptic vesicles fuses with the plasma membrane. (presynaptic membrane) to thereby open a fusion pore in the synaptic vesicle membrane. Then, neurotransmitters in the synaptic vesicle are transported through the pore.
- The present inventor has found that
inositol - Thus, it is believed that various substances are involved in the interaction of synaptic vesicles with the presynaptic membrane.
- It is an object of the invention to provide a Synaptotagmin-binding and yet cytoplasmic RNA-binding protein.
- Toward the solution of the above problem, the present inventor has analyzed those proteins capable of binding to Synaptotagmin and succeeded in isolating a protein which binds to Synaptotagmin and yet can bind to cytoplasmic RNA. Thus, the present invention has been achieved.
- The present invention relates to the following inventions:
- (1) A recombinant protein selected from the group consisting of the following (a) and (b):
-
- (a) a protein comprising the amino acid sequence as shown in SEQ ID NO: 2
- (b) a protein which comprises the amino acid sequence as shown in SEQ ID NO: 2 having deletion, substitution or addition of one or several amino acids and which has RNA binding activity.
- (2) A recombinant protein selected from the group consisting of the following (c) and (d):
-
- (c) a protein comprising the amino acid sequence as shown in SEQ ID NO: 4
- (d) a protein which comprises the amino acid sequence as shown in SEQ ID NO: 4 having deletion, substitution or addition of one or several amino acids and which has RNA binding activity.
- (3) A gene encoding a protein selected from the group consisting of the following (a) and (b):
-
- (a) a protein comprising the amino acid sequence as shown in SEQ ID NO: 2
- (b) a protein which comprises the amino acid sequence as shown in SEQ ID NO: 2 having deletion, substitution or addition of one or several amino acids and which has RNA binding activity.
- (4) A gene encoding a protein selected from the group consisting of the following (c) and (d):
-
- (c) a protein comprising the amino acid sequence as shown in SEQ ID NO: 4
- (d) a protein which comprises the amino acid sequence as shown in SEQ ID NO: 4 having deletion, substitution or addition of one or several amino acids and which has RNA binding activity.
- (5) A gene comprising a DNA selected from the group consisting of the following (e) and (f):
-
- (e) a DNA comprising the nucleotide sequence as shown in SEQ ID NO: 1
- (f) a DNA which hybridizes to the nucleotide sequence as shown in SEQ ID NO: 1 under stringent conditions and which encodes a protein having RNA binding activity.
- (6) A gene consisting of a DNA selected from the group consisting of the following (g) and (h):
-
- (g) a DNA comprising a nucleotide sequence spanning from
position 154 to position 1836 of SEQ ID NO: 3 - (h) a DNA which hybridizes to a DNA comprising a nucleotide sequence spanning from
position 154 toposition 1836 of SEQ ID NO: 3 and which encodes a protein having RNA binding activity.
- (g) a DNA comprising a nucleotide sequence spanning from
- (7) A recombinant vector comprising the gene.
- (8) A transformant comprising the recombinant vector.
- (9) A method of producing an RNA-binding protein comprising culturing the above transformant and recovering the RNA-binding protein from the resultant culture.
- (10) An antibody against the protein.
- (11) A pharmaceutical composition for regulating neuronal functions, comprising the protein as an active ingredient.
- (12) A therapeutic agent for neurological diseases comprising the protein as an active ingredient.
- (13) A reagent for detecting a Synaptotagmin-binding and yet RNA-binding protein, comprising an antibody against the protein.
- (14) A reagent for detecting Synaptotagmin, comprising the protein and/or an antibody against the protein.
-
FIG. 1 shows cDNA clones of various lengths encoding the protein of the invention, SYNCRIP, (panel A) and the construction of truncated SYNCRIP genes (panel B). -
FIG. 2 shows an alignment between the amino acid sequence of SYNCRIP and the amino acid sequence of hnRNP R. -
FIG. 3 shows photographs indicating cytoplasmic localization of SYNCRIP. -
FIG. 4 shows the expression of SYNCRIP in subcellular fractions. -
FIG. 5 shows the expression of SYNCRIP during the postnatal development in mouse. -
FIG. 6 shows the expression pattern of SYNCRIP in mouse tissues. -
FIG. 7 shows the results of binding experiments between SYNCRIP and RNA molecules. -
FIG. 8 shows the results of reactivity experiments on antibodies against truncated SYNCRIP proteins (anti-A SYNCRIP antibodies). -
FIG. 9 shows the interaction of SYNCRIP with the C2A and/or C2B domain of Syt. -
FIG. 10 shows the interaction of a C-terminal region of SYNCRIP with the C2A or C2B domain of Syt. -
FIG. 11 shows the results of an immunohistochemical assay. The same cryosection was probed with anti-SYNCRIP-N antibody (panel A) and anti-Syt-I antibody (panel B). EGL: external germinal layer; ML: molecular layer; PL: Purkinje cell layer; IGL: internal granule layer. -
FIG. 12 shows the interaction of SYNCRIP with Syt isoforms. -
FIG. 13 shows the interaction of SYNCRIP with Syt isoforms in cells. - The protein of the invention is a Synaptotagmin-binding and yet cytoplasmic RNA-binding protein designated SYNCRIP (Synaptotagmin-binding, cytoplasmic RNA-interacting protein)(molecular weight: 66 kDa). One region of SYNCRIP binds to cytoplasmic RNA (in particular, poly(A) region of mRNA) and another region of SYNCRIP binds to the C2B domain of Synaptotagmin on synaptic vesicles. Since synaptic vesicles are transported to the presynaptic terminal after their production in the neurosome, SYNCRIP functions as a “vehicle” for RNA.
- As described above, the binding of an inositol high polyphosphate to the C2B domain of Syt inhibits the fusion step of synaptic vesicles with the presynaptic membrane. With respect to this inhibition, the present inventor has analyzed those molecules which interact directly with the C2A and C2B domains of Syt. As a result, a protein which binds to Synaptotagmin and yet binds to cytoplasmic RNA has been found.
- 1. Isolation of Genes Encoding SYNCRIP
- (1) Preparation and Screening of cDNA Library
- The gene of the invention can be isolated by screening a cDNA library prepared from mRNA extracted from mouse or rat cerebellum using a DNA probe synthesized based on a partial amino acid sequence of SYNCRIP purified from cerebellum.
- The preparation of mRNA may be performed by conventional techniques. For example, cerebellum tissues or cells are treated with a guanidine reagent or phenol reagent to obtain total RNA. Then, poly(A+) RNA (mRNA) is obtained therefrom by the affinity column method using oligo(dT)-cellulose or poly U-Sepharose using Sepharose 2B as a carrier, or by the batch method. Alternatively, poly(A+) RNA fraction may be obtained by sucrose density-gradient centrifugation.
- With the resultant mRNA as a template, a single-stranded cDNA is synthesized using oligo(dT) primers and a reverse transcriptase. Then, a double-stranded cDNA is synthesized from the single-stranded cDNA. The thus obtained double-stranded cDNA is integrated into an appropriate cloning vector to prepare a recombinant vector. A host such as E. coli is transformed with the recombinant vector. The resultant transformants are selected using tetracycline resistance and ampicillin resistance as indicators to thereby obtain a cDNA library.
- The transformation of E. coli may be performed by conventional techniques. For example, the method of Hanahan (Hanahan, D. (1983) J. Mol. Biol. 166, 557-580) in which a recombinant vector is added to competent cells prepared with calcium chloride, magnesium chloride or rubidium chloride may be used. When a plasmid is used as a vector, the plasmid should contain drug resistance genes against tetracycline, ampicillin, etc. Alternatively, cloning vectors other than plasmid (such as λ phage) may be used.
- As a screening method to select those clones having a DNA of interest from the resultant transformants, a method may be used in which a pair of primers are synthesized based on a partial amino acid sequence of SYNCRIP purified from mouse cerebellum, and then a polymerase chain reaction (PCR) is performed using the primers. The purification of SYNCRIP from mouse cerebellum may be performed by suspending the cerebellum in an appropriate buffer, removing cell debris by centrifugation, incubating the homogenate with GST-Syt-II C2AB protein, eluting the bound proteins, separating the proteins by ion exchange chromatography and subjecting the resultant 66 kDa protein-rich fractions to SDS-PAGE.
- As a template DNA to be used in the above PCR, a cDNA synthesized from the mRNA by reverse transcription may be given. The primers may be designed based on amino acid sequence information on the purified SYNCRIP, taking into consideration of the expected size of the DNA fragment to be amplified and combinations of regenerate codons. For example, the sense primer may be 5′-GTNACNGA(AG)GGN(TC)TNAC-3′ (SEQ ID NO: 8) based on a partial sequence VTEGLT (SEQ ID NO: 6); and the anti-sense primer may be 5′-(TC)TT(AG)TC(AG)TCNGG(TC)TG(AG)TG(AG)TA-3′ (SEQ ID NO: 9) based on a partial sequence YHQPDDK (SEQ ID NO: 7). It should be noted that primers which may be used in the PCR are not limited to these primers.
- The thus amplified DNA fragment is labeled with such as 32P, 35S or biotin, and hybridized as a probe with a nitrocellulose filter on which the DNA from the transformant has been denatured and immobilized. Thus, positive clones are obtained.
- (2) Determination of Nucleotide Sequences
- The nucleotide sequences of the thus obtained clones are determined. This sequencing may be performed by conventional techniques such as the chemical modification method of Maxam-Gilbert or the dideoxynucleotide chain termination method using M13 phage. However, sequencing is usually performed with an automated DNA sequencer (e.g., Perkin Elmer model 373A DNA Sequencer; BcaBEST Dideoxy Sequencing Kit (TAKARA)).
- The nucleotide sequence of the gene of the invention (full-length cDNA) is shown in SEQ ID NO: 3, and the amino acid sequence of the protein of the invention in SEQ ID NO: 4. In the nucleotide sequence of SEQ ID NO: 3, an open reading frame is formed by a nucleotide sequence from
position 154 toposition 1836, which encodes the amino acid sequence of SEQ ID NO: 4. Therefore, in addition to the gene consisting of the nucleotide sequence of SEQ ID NO: 3, a gene consisting of the above mentioned nucleotide sequence of the open reading frame region is also included in the gene of the invention. - It should be note that as long as a protein consisting of the amino acid sequence as shown in SEQ ID NO: 4 has RNA binding activity, in particular, activity to bind to the poly(A) sequence of mRNA, the amino acid sequence may have mutations such as deletion, substitution or addition of one or more of amino acids. For example, one or several, preferably about one to ten, more preferably one to five amino acids in the amino acid sequence as shown in SEQ ID NO: 4 may be deleted; one or several, preferably about one to ten, more preferably one to five amino acids may be added to the amino acid sequence as shown in SEQ ID NO: 4; or may be deleted; one or several, preferably about one to ten, more preferably one to five amino acids in the amino acid sequence as shown in SEQ ID NO: 4 may be replaced with other amino acids.
- In the present invention, the term “RNA binding activity” means an activity of a region of SYNCRIP to bind to cytoplasmic RNA (in particular, the poly(A) region of mRNA).
- Truncated versions of the protein having the amino acid sequence of SEQ ID NO: 4 are also included in the protein of the invention, as long as they have the RNA binding activity described above. Since a truncated SYNCRIP lacking amino acids 401-561 in SEQ ID NO: 4 (C-terminal truncated version) loses RNA binding activity, it can be said that the region of amino acids 401-561 possesses the RNA-binding activity and that the region of amino acids 1-400 does not have any effect on the RNA-binding activity of SYNCRIP. Therefore, a protein having the amino acid sequence of the above-mentioned positions 401-561 (SEQ ID NO: 2) (i.e., the amino acid sequence of SEQ ID NO: 4 lacking amino acids 1-400) is also included in the protein of the invention, for example. Further, a protein comprising the amino acid sequence as shown in SEQ ID NO: 4 may have mutations such as deletion, substitution of addition of one to several, preferably one to ten, and more preferably one to five amino acids within the region which does not have any effect on the RNA-binding activity (i.e., the region of amino acids 1-400 in SEQ ID NO: 4). Further, the above-described truncated proteins which have mutation(s) in one or several amino acids are also included in the protein of the invention, as long as they have RNA binding activity.
- Accordingly, genes encoding proteins having the above-described mutation-introduced amino acid sequences, or genes encoding truncated SYNCRIP proteins or mutated versions thereof are also included in the gene of the invention as long as the proteins encoded by them have RNA binding activity.
- The protein of the invention, SYNCRIP, is a protein which can also binds to Synaptotagmin. As long as the protein of the invention has the ability to bind to Synaptotagmin, the target of binding may be any of the isoforms of Syt-I to -XI. Preferably, the protein of the invention binds to Syt-I and -II.
- Furthermore, a DNA which can hybridize to the above-described gene of the invention under stringent conditions is also included in the gene of the invention. The term “stringent conditions” means, for example, sodium concentrations of 600-900 mM and temperatures of 60-68° C., preferably 65° C.
- The introduction of a mutation into a gene may be performed by known techniques such as the method of Kunkel or the gapped duplex method, or by techniques based on these methods. For example, a mutation may be introduced with a commercial mutagenesis kit using the site-specific mutagenesis technique (e.g., Mutant-K or Mutant-G; Takara) or LA PCR in vitro Mutagenesis Series kit (Takara).
- Once the nucleotide sequence of the gene of the invention has been determined, the gene of the invention can be obtained by chemical synthesis, by PCR using the cDNA of the gene as a template, or by hybridizing a DNA fragment having the nucleotide sequence of the gene as a probe.
- 2. Preparation of Recombinant Vectors and Transformants
- (1) Preparation of Recombinant Vectors
- The recombinant vector of the invention can be obtained by ligating (inserting) the gene of the invention into an appropriate vector. The vector into which the gene of the invention is to be inserted is not particularly limited as long as it is replicable in a host. For example, plasmid DNA, phage DNA or the like may be used.
- Specific examples of plasmid DNA which may be used in the invention include E. coli-derived plasmids (e.g., pREST, pBR322, pBR325, pUC118, pUC119, pUC18 and pUC19), Bacillus subtilis-derived plasmids (e.g., pUB110 and pTP5) and yeast-derived plasmids (e.g., YEp13, YEp24 and YCp50). Specific examples of phage DNA which may be used in the invention include λ phages (e.g., Charon4A, Charon21A, EMBL3, EMBL4, λgt10, λgt11 and λZAP). Further, an animal virus vector such as retrovirus or vaccinia virus; or an insect virus vector such as baculovirus may also be used.
- For insertion of the gene of the invention into a vector, a method may be employed in which the purified DNA is digested with an appropriate restriction enzyme and then inserted into the restriction site or multi-cloning site of an appropriate vector DNA for ligation.
- The gene of the invention must be operably linked to the vector. For this purpose, the vector of the invention may contain, if desired, cis elements such as an enhancer, a splicing signal, a poly(A) addition signal, selection markers, a ribosome binding sequence (SD sequence) or the like in addition to a promoter and the gene of the invention. As the selection marker, dihydrofolate reductase gene, ampicillin resistance gene, neomycin resistance gene, or the like may be enumerated.
- (2) Preparation of Transformants
- The transformant of the invention may be obtained by introducing the recombinant vector of the invention into a host so that the gene of interest can be expressed. The host is not particularly limited as long as it can express the DNA of the invention. Specific examples of hosts which may be used in the invention include Escherichia bacteria such as E. coli; Bacillus bacteria such as Bacillus subtilis; Pseudomonas bacteria such as Pseudomonas putida; and Rhizobium bacteria such as Rhizobium meliloti. Further, yeasts such as Saccharomyces cerevisiae, Schizosaccharomyces pombe; animal cells such as COS cells, CHO cells; and insect cells such as Sf9 cells, Sf21 cells may be used.
- When a bacterium such as E. coli is used as a host, the recombinant vector of the invention is preferably not only capable of autonomous replication in the host but also composed of a promoter, a ribosome binding sequence, the gene of the invention and a transcription termination sequence. The vector may also contain a gene that controls the promoter.
- Specific examples of E. coli strains which may be used in the invention include E. coli K12 and DH1. Specific examples of Bacillus bacteria which may be used in the invention include Bacillus subtilis strains. As a promoter, any promoter may be used as long as it can direct the expression of the gene of the invention in a host such as E. coli. For example, an E. coli- or phage-derived promoter such as trp promoter, lac promoter, PL promoter or PR promoter may be used. Alternatively, an artificially altered promoter such as tac promoter may also be used. As a method for introducing the recombinant vector into a bacterium, any method of DNA transfer into bacteria may be used. For example, a method using calcium ions (Cohen, S. N. et al., Proc. Natl. Acad. Sci., USA, 69:2110-2114 (1972)) or electroporation may be used.
- When yeast is used as the host, Saccharomyces cerevisiae, Schizosaccharomyces pombe or Pichia pastoris may be used, for example. A promoter which may be used in this case is not particularly limited. Any promoter may be used as long as it can direct the expression of the gene of the invention in yeast. For example, GAL1 promoter, GAL10 promoter, heat shock protein promoter, MFα1 promoter, PH05 promoter, PGK promoter, GAP promoter, ADH promoter, or AOX1 promoter may be enumerated. As a method of introducing the recombinant vector into yeast, any method of DNA transfer into yeast may be used. For example, electroporation (Becker, D. M.,. Methods Enzymol., 194:182-187 (1990)), the spheroplast method (Hinnen, A. et al., Proc. Natl. Acad. Sci., USA, 75:1929-1933 (1978)), or the lithium acetate method (Itoh, H., J. Bacteriol., 153:163-168 (1983)) may be enumerated.
- When an animal cell is used as the host, simian COS-7 or Vero cells, Chinese hamster ovary cells (CHO cells), mouse L cells, rat GH3 cells, human FL cells; or the like may be used. As a promoter, SRα promoter, SV40 promoter, LTR promoter, CMV promoter or the like may be used. The early gene promoter of human cytomegalovirus may also be used. As a method of introducing the recombinant vector into an animal cell, electroporation, the calcium phosphate method, or lipofection may be used, for example.
- When an insect cell is used as the host, Sf9 cells, Sf21 cells or the like may be used. As a method for introducing the recombinant vector into an insect cell, the calcium phosphate method, lipofection, or electroporation may be used, for example.
- 3. Production of SYNCRIP
- The protein of the invention can be obtained by culturing the above-described transformant and recovering the protein from the resultant culture. The term “culture” means any of the following materials: culture supernatant, cultured cells or microorganisms, or disrupted products from cultured cells or microorganisms. The cultivation of the transformant of the invention is carried out in accordance with conventional methods commonly used for culturing hosts.
- As a medium to culture the transformant obtained from a microorganism host such as E. coli or yeast, either a natural or synthetic medium may be used as long as it contains carbon sources, nitrogen sources and inorganic salts assimilable by the microorganism and is capable of effective cultivation of the transformant. As carbon sources, carbohydrates such as glucose, fructose, sucrose, starch; organic acids such as acetic acid, propionic acid; and alcohols such as ethanol and propanol may be used. As nitrogen sources, ammonia; ammonium salts of inorganic or organic acids such as ammonium chloride, ammonium sulfate, ammonium acetate, ammonium phosphate; other nitrogen-containing compounds; Peptone; meat extract; corn steep liquor and the like may be used. As inorganic substances, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, magnesium phosphate, magnesium sulfate, sodium chloride, iron(II) sulfate, manganese sulfate, copper sulfate, calcium carbonate and the like may be used.
- Usually, the cultivation is carried out under aerobic conditions (such as shaking culture or aeration agitation culture) at 37° C. for 6 to 24 hrs. During the cultivation, the pH is maintained at 7.0 to 7.5. The pH adjustment is carried out using an inorganic or organic acid, or an alkali solution or the like. During the cultivation, an antibiotic such as ampicillin or tetracycline may be added to the medium if necessary.
- When a microorganism transformed with an expression vector containing an inducible promoter is cultured, an inducer may be added to the medium if necessary. For example, when a microorganism transformed with an expression vector containing lac promoter is cultured, isopropyl-β-D-thiogalactopyranoside (IPTG) may be added to the medium. When a microorganism transformed with an expression vector containing trp promoter is cultured, indoleacrylic acid (IAA) may be added to the medium.
- As a medium to culture a transformant obtained from an animal cell as a host, commonly used RPMI1640 medium or DMEM medium, or one of these media supplemented with fetal bovine serum, etc. may be used. Usually, the cultivation is carried out in the presence 5% CO2 at 37° C. for 1 to 30 days. During the cultivation, antibiotics such as kanamycin or penicillin may be added to the medium if necessary.
- After the cultivation, SYNCRIP protein of the invention is recovered by disrupting the microorganisms or cells, if the protein is produced within the microorganisms or cells. If SYNCRIP protein of the invention is produced outside the microorganisms or cells, the culture fluid is used as it is or subjected to centrifugation to remove the microorganisms or cells. Thereafter, the resultant supernatant is subjected to conventional biochemical techniques used for isolating/purifying proteins. These techniques include ammonium sulfate precipitation, gel chromatography, ion exchange chromatography and affinity chromatography, and may be used independently or in an appropriate combination. Thus, SYNCRIP protein of the invention can be isolated and purified from the above-mentioned culture.
- 4. Antibodies against SYNCRIP
- (1) Preparation of Antigen
- In the present invention, antibodies against SYNCRIP may be prepared using the SYNCRIP isolated and purified as described above or a fragment thereof as an antigen.
- (2) Preparation of Polyclonal Antibodies against SYNCRIP of the Invention
- Animals are immunized with the antigen prepared as described above. If the animal is rabbit, the dose of the antigen is 100-500 μg/rabbit when an adjuvant is used. Examples of adjuvants useful in the present invention include Freund's complete adjuvant (FCA), Freund's incomplete adjuvant (FIA) and aluminium hydroxide adjuvant.
- Immunization is carried out by administering the antigen to a mammal (e.g., rat, mouse or rabbit). The antigen is administered intravenously, subcutaneously or intraperitoneally. The interval of immunization is not particularly limited. Immunization is carried out 1 to 10 times, preferably 2 to 3 times, at intervals of several days to several weeks, preferably 2 to 3 weeks. Antibody titer is determined daily from day 6 to day 60 after the final immunization. When the maximum antibody titer is shown, blood is taken from the animal to thereby obtain an anti-serum. The determination of antibody titer may be performed by ELISA (enzyme-linked immunosorbent assay), RIA (radioimmunoassay) or the like.
- If purification of an antibody from the anti-serum is needed, purification may be performed by conventional methods such as ammonium sulfate salting out, ion exchange chromatography, gel filtration or affinity chromatography. These methods may be used independently or in combination.
- (3) Preparation of Monoclonal Antibodies against SYNCRIP of the Invention
- (3-1) Immunization and Recovery of Antibody-Producing Cells
- Animals are immunized with the antigen prepared as described above. If necessary, an adjuvant (commercial Freund's complete adjuvant, Freund's incomplete adjuvant, etc.) may be mixed with the antigen for efficient immunization.
- Immunization is carried out by administering the antigen to a mammal (e.g., rat, mouse or rabbit). If the animal is mouse, the dose of the antigen per administration is 50 μg/mouse. In principle, the antigen is administered intravenously, subcutaneously or intraperitoneally. The interval of immunization is not particularly limited. Immunization is carried out at least 2 to 3 times at intervals of several days to several weeks, preferably 2 to 3 weeks. After the final immunization, antibdy-producing cells are recovered. Examples of antibody-producing cells include spleen cells, lymph node cells and peripheral blood cells. Among all, spleen cells are preferable.
- (3-2) Cell Fusion
- In order to obtain hybridomas, antibody-producing cells and myeloma cells are fused. As myeloma cells to be fused with antibody-producing cells, a commonly available cell strain derived from an animal such as mouse may be used. Preferable cell strains are those which have drug selectivity and cannot survive in HAT selection medium (containing hypoxanthine, aminopterin and thymidine) when unfused, but can survive therein only when fused with antibody-producing cells. Specific examples of myeloma cells useful in the present invention include mouse myeloma cell strains P3X63-Ag.8.U1 (P3U1), P3/NSI/1-Ag4-1 and Sp2/0-Ag14.
- Cell fusion between the above-described myeloma cells and antibody-producing cells is performed as follows. Briefly, the antibody-producing cells and myeloma cells are mixed at a ratio between 15:1 and 25:1 in an animal cell culture medium such as serum-free DMEM or RPMI-1640. Then, fusion reaction is performed in the presence of a cell fusion promoter such as polyethylene glycol, or by electric pulse treatment (e.g., electroporation).
- (3-3) Selection and Cloning of Hybridomas
- Hybridomas of interest are selected from fused cells. For example, fused cells are cultured in a medium containing hypoxanthine, aminopterin and thymidine. Then, cells growing therein are obtained as hybridomas.
- Subsequently, culture supernatants of grown hybridomas are screened for the presence of antibodies of interest. The screening of hybridomas may be performed by any of the conventional methods. For example, a part of the culture supernatant contained in a well in which a hybridoma is growing may be taken and screened by ELISA, RIA or the like. The cloning of fused cells is performed by, for example, the limiting dilution method. Finally, hybridomas which are monoclonal antibody-producing cells are established.
- (3-4) Recovery of Monoclonal Antibodies
- The recovery of monoclonal antibodies from the established hybridomas may be performed by conventional cell culturing methods. Briefly, the hybridomas are cultured in an animal cell culture medium (such as 10% fetal bovine serum-containing RPMI-1640 or MEM medium) under conventional culture conditions (e.g., at 37° C., under 5% CO2) for 3 to 10 days. Then, antibodies are recovered from culture supernatants.
- In the above-described method for recovering antibodies, the antibodies may be purified, if necessary, by conventional methods such as ammonium sulfate fractionation, ion exchange chromatography, affinity chromatography and gel chromatography. These methods may be used independently or in combination.
- 5. Pharmaceutical Compositions for Regulating Neuronal Functions
- As described above, the protein of the invention can bind to both RNA and Synaptotagmin, and Synaptotagmin moves from the neurosome to the nerve terminal. Therefore, the protein of the invention performs a function of transporting RNA molecules encoding neurotransmitters to the nerve terminal. Accordingly, the gene or the protein of the invention may be used as a regulator for allowing the expression of neurotransmitters at the nerve terminal, i.e., as a pharmaceutical for regulating neuronal functions. The gene or the protein of the invention is useful as an activator for neurons or an agent for gene therapy for neurological diseases.
- The therapeutic agent or agent for gene therapy of the invention can be administered orally or parenterally and systemically or locally.
- When the protein or the gene of the invention is used as a therapeutic agent or an agent for gene therapy for neurological diseases, the target of use is not particularly limited. For example, the agent of the invention may be used for a specific purpose of treating or preventing neurological diseases such as Parkinson's disease and Alzheimer's disease which develop when neurotransmission does not function or is decreased. Such a disease may be an independent disease, or may be complicated with other neurological disease, or may be complicated with even a disease other than neurological diseases; in any case, such a disease may be the target of use of the protein or gene of the invention.
- When the regulator of the invention is administered orally, the regulator may be prepared into any of the formulations such as tablets, capsules, granules, powder, pills, troches, internal liquid agents, suspensions, emulsions or syrups. Alternatively, the regulator may be prepared into a dry product which is re-dissolved just before use. When the regulator of the invention is administered parenterally, the regulator may be formulated into intravenous injections (including drops), intramuscular injections, intraperitoneal injections, subcutaneous injections, suppositories, or the like. Injections are supplied in the form of unit dosage ampules or multi-dosage containers.
- These formulations may be prepared by conventional methods using appropriate excipients, fillers, binders, wetting agents, disintegrating agents, lubricating agents, surfactants, dispersants, buffers, preservatives, dissolution aids, antiseptics, flavoring/perfuming agents, analgesics, stabilizers, isotonic agents, etc. conventionally used in pharmaceutical preparations.
- Each of the above-described formulations may contain pharmaceutically acceptable carriers or additives. Specific examples of such carriers or additives include water, pharmaceutically acceptable organic solvents, collagen, polyvinyl alcohol, polyvinyl pyrrolidone, carboxyvinyl polymers, sodium alginate, water-soluble dextran, sodium carboxymethyl starch, pectin, xanthan gum, gum arabic, casein, gelatin, agar, glycerol, propylene glycol, polyethylene glycol, vaseline, paraffin, stearyl alcohol, stearic acid, human serum albumin, mannitol, sorbitol and lactose. One or a plurality of these additives are selected or combined appropriately depending of the form of the preparation.
- The dosage levels of the therapeutic agent of the invention will vary depending on such factors as the age of the subject, the route of administration and the number of times of administration, and may be varied in a wide range. When an effective amount of the protein of the invention is administered in combination with an appropriate diluent and a pharmaceutically acceptable carrier, the effective amount of the protein may be in the range from 0.01 to 1000 mg/kg body weight per administration. The therapeutic agent may be administered once a day or in several dosages per day.
- When the gene of the invention is used as an agent for gene therapy to treat neurological diseases, the gene of the invention may be directly administered by injection, or a vector incorporating the gene of the invention may be administered. Specific examples of a suitable vector for this purpose include an adenovirus vector, adeno-associated virus vector, herpes virus vector, vaccinia virus vector and retrovirus vector. By using such a virus vector, the gene of the invention can be administered efficiently. Alternatively, the gene of the invention may be enclosed in phospholipid vesicles such as liposomes, and the resultant liposomes may be administered to the subject. Since liposomes are closed vesicles containing a biodegradable material, the gene of the invention and liposomes are mixed so that the gene is retained in the internal aqueous layer and lipid bilayer of the liposomes (a liposome-gene complex is formed). Subsequently, when this complex is cultured with cells, the gene in the complex is taken into the cells (lipofection). Then, the resultant cells may be administered by the methods as described below.
- As a method of administration of the agent for gene therapy of the invention, local administration to the central nervous system (such as the brain, spiral cord) may be performed in addition to conventional systemic administration such as intravenous or intra-arterial administration. Further, an administration method combined with catheter techniques or surgical operations may also be employed.
- The dosage levels of the agent for gene therapy of the invention vary depending on such factors as the age, sex and conditions of the subject, the route of administration, the number of times of administration, and the type of the formulation. Usually, it is appropriate to administer the gene of the invention in an amount of 0.1-100 mg/adult body per day.
- 6. Reagents for Detecting SYNCRIP
- Since the antibody of the invention reacts with SYNCRIP or a fragment thereof, the antibody may be used as a reagent for detecting SYNCRIP. The method of detection of SYNCRIP is not particularly limited. For example, Western blotting may be employed. A test sample (e.g., cell component or subcellular fraction) is fractionated by such as electrophoresis and then reacted with the antibody of the invention which has been labeled (e.g., radioactively or fluorescently) in advance, followed by detection of signals.
- The antibody used for the detection of SYNCRIP may be either an antibody against a protein having the full-length amino acid sequence of SYNCRIP or an antibody against a peptide having a partial amino acid sequence of SYNCRIP.
- 7. Reagents for Detecting Synaptotagmin
- Since SYNCRIP of the invention or a fragment thereof (e.g., truncated SYNCRIP) can bind to Synaptotagmin, the protein or the fragment thereof may be used as a reagent for detecting Synaptotagmin. Synaptotagmin contains C2A and C2B domains, and SYNCRIP binds to the C2B domain. Thus, in the present invention, the C2B domain of Synaptotagmin can be the target of detection.
- The detection of Synaptotagmin may be performed by reacting a test sample (cell lysate) with SYNCRIP or a fragment thereof and subjecting the reaction product to Western blotting. For example, a cell lysate or subcellular fraction containing Synaptotagmin is fractionated by electrophoresis and then reacted with SYNCRIP or a fragment thereof pre-labeled radioactively or fluorescently, followed by detection of signals. Alternatively, a fusion protein between Synaptotagmin and GST (glutathione-S-transferase) is prepared by conventional methods and then reacted with SYNCRIP. The reaction product is recovered with glutathione-Sepharose and subjected to Western blotting to detect signals.
- In the above Western blotting, a labeled antibody against SYNCRIP or a fragment thereof is used to determine signals generated by the antibody. Thus, the antibody may also be used as a reagent for detecting Synaptotagmin.
- Hereinbelow, the present invention will be described more specifically with reference to the following Examples. However, the technical scope of the present invention is not limited to these Examples.
- (1) Determination of Partial Amino Acid Sequences of SYNCRIP from Mouse Brain
- SYNCRIP was partially purified as previously described (Mizutani, A. et al. (1997) Biochem Biophys. Res. Commun. 240, 128-131) with some improvement.
- Briefly, whole brains (50 g in wet weight) from 8-week old DDY mice were homogenized in 250 ml of a solution containing the following components using a glass-Teflon homogenizer (930 rpm, 10 strokes):
-
- 10 mM HEPES-NaOH (pH 7.4)
- 140 mM NaCl
- 2 mM EDTA
- 1 mM β-Mercaptoethanol
- 0.2 mM Phenylmethylsulfonyl fluoride (PMSF)
- 10 μM Pepstatin A
- After removal of cell debris and nuclear crude fractions by low-speed centrifugation (1,000×g, 10 min), Triton X-100 was added to give a supernatant fraction (S1) with a final concentration of 1% (w/v). This fraction (S1) was left on ice for 30 min, and then ultracentrifuged at 16,000×g for 30 min to obtain a soluble fraction, which was incubated with purified GST-Syt-II C2AB protein (5 mg) at 4° C. for 4 hr. To the resultant mixture, 1 ml (50% slurry) of glutathione-Sepharose was added and incubated at 4° C. for 1 hr. After extensive washing with a wash buffer (10 mM HEPES-NaOH (pH 7.4), 140 mM NaCl, 2 mM EDTA and 1 mM β-mercaptoethanol), the bound proteins were eluted with 100 μM IP6 in the wash buffer. The eluted proteins were separated further by MonoA ion exchange chromatography.
- As a result, a 66 kDa protein was eluted at around 0.2 M NaCl, pH 8.0. Fractions rich in the 66 kDa protein were subjected to 10% SDS-polyacrylamide gel electrophoresis followed by staining with Coomassie Brilliant Blue R. The 66 kDa protein band was cut out from the gel and digested with lysylendopeptidase (Wako Purechemical) as described previously (Rosenfeld, J. et al. (1992) Annal. Biochem. 203, 173-179). The resultant polypeptides were separated with a C-18 reversed-phase column (MRPC C2/C18 SC 2.1/10; Amersham Pharmacia Biotech) connected to SMART system (Amersham Pharmacia Biotech). Peptide sequences for individual peptides were determined with Perkin Elmer Biosystems 492 protein sequencer.
- (2) Cloning of a cDNA Encoding the 66 kDa Protein SYNCRIP
- A pair of degenerate primers corresponding to partially digested peptide 1 (VTEGLTDVILYHQPDDK; SEQ ID NO: 5) were synthesized. Sense primer was based on the sequence VTEGLT (SEQ ID NO: 6), and anti-sense primer was based on the sequence YHQPDDK (SEQ ID NO: 7).
-
- Sense primer: 5′-GTNACNGA(AG)GGN(TC)TNAC-3′ (SEQ ID NO: 8)
- Anti-sense primer: 5′-(TC)TT(AG)TC(AG)TCNGG(TC)TG(AG)TG(AG)TA-3′ (SEQ ID NO: 9)
- With these primers, PCR was performed for 35 cycles (at 94° C. for 30 sec, at 55° C. for 1 min and at 72° C. for 1 min) using a random-primed, mouse cerebellum-derived first strand cDNA as a template and a Takara PCR kit. The resultant 51 bp PCR product was cloned into pT7Blue (Novagen) followed by confirmation of the sequence thereof.
- This 51 bp fragment was labeled with [α-32P] dCTP (Amersham Pharmacia Biotech) and used as a probe for screening about 5.0×105 plaques from a mouse cerebellum-derived cDNA library.
- Partial amino acid sequences of the 66 kDa protein were determined as described above, and cDNAs were isolated based on the amino acid sequences determined. As a result, several clones partially overlapping were obtained (
FIG. 1A ). Using a 5′- or 3′-end fragment (about 200 bp) of clone 1a (FIG. 1 ) as a hybridization probe, a λgt cDNA library was screened to thereby obtain a cDNA encoding the full-length SYNCRIP. The cloned cDNA was subcloned into pBluescript and sequenced in both directions by the dideoxy chain termination method (BcaBEST Dideoxy Sequencing Kit; Takara). - The nucleotide sequence of the gene (cDNA) encoding the full-length SYNCRIP is shown in SEQ ID NO: 3. The amino acid sequence of SYNCRIP (open reading frame) is shown in SEQ ID NO: 4.
- The homology analysis of the deduced amino acid sequence of the cloned cDNA revealed that this amino acid sequence is highly homologous to human heterogeneous nuclear ribonucleoprotein R (hnRNP R) (
FIG. 2 ). hnRNP R is a 82 kDa protein defined by Hassefeld et al. (Hassefeld, W. et al. (1998) Nucleic Acids Res. 26, 439-445). This protein is known to be localized in the nucleoplasm and, as described later, is completely different from SYNCRIP of the invention in terms of function. - (1) Localization of SYNCRIP
- In this Example, both SYNCRIP and hnRNP R were expressed in COS-7 cells and their behaviors were examined in order to confirm the region of expression of SYNCRIP within cells as well as to demonstrate that SYNCRIP and hnRNP R are functionally different substances. The procedures were as described below.
- For transient expression of SYNCRIP in COS-7 cells, an EcoRI site and an XhoI site were introduced by PCR to the 5′- and 3′-ends of the full-length SYNCRIP cDNA, respectively. The resultant DNA fragment was subcloned into plasmid pCDNA3 (Invitrogen). This gene construct was transfected into COS-7 cells with Lipofectamine reagent (Life Technologies) according to the manufacturer's instructions.
- On the other hand, two types of polyclonal antibodies against SYNCRIP were prepared for the purpose of Western blotting. One is against an N-terminal region of SYNCRIP (the boxed region in
FIG. 2 ) and designated anti-SYNCRIP-N antibody. The other is against a region with complete homology between SYNCRIP and hnRNP R (the double underlined region inFIG. 2 ) and designated anti-SYNCRIP-Pep antibody. - These antibodies were prepared as described below.
- (i) Anti-SYNCRIP-N Antibody
- A (His)6-tagged recombinant protein comprising the N-terminal region of SYNCRIP (amino acids 1-170) was expressed in E. coli and partially purified with ProBond resin (Invitrogen). Then, the protein was fully purified by MonoQ column chromatography. Three hundred micrograms of the purified protein was administered to Japan White rabbits together with Freund's complete adjuvant for immunization (subcutaneous injection, at intervals of 14 days). On the other hand, a GST fusion protein containing a region corresponding to the above antigenic protein was covalently bound to a carrier and packed in a column to thereby prepare an affinity column. Blood was collected from the rabbit to obtain a serum, which was then applied to the affinity column to purify anti-SYNCRIP-N antibody.
- (ii) Anti-SUYNCRIP-Pep Antibody
- An antibody against a peptide having amino acids 140-152 of SYNCRIP was prepared from rabbits using this peptide (to which a Cys residue was artificially introduced at its N-terminus) crosslinked with keyhole limpet hemocyanin. The anti-peptide antibody (i.e., anti-SYNCRYP-Pep antibody) was affinity-purified with the antigenic peptide-conjugated beads.
- These antibodies reacted with SYNCRIP and also with hnRNP (82 kDa) and a degradation product thereof (74 kDa) (
FIG. 8 ). When the full-length SYNCRIP cDNA was transfected into COS-7 cells, SYNCRIP was over-expressed and localized in the cytoplasm in both cases examined with anti-SYNCRIP-N antibody and anti-SYNCRIP-Pep antibody (FIG. 3A -B). Panels A and B inFIG. 3 demonstrated that SYNCRIP is not localized in the nucleus but localized in the cytoplasm. InFIG. 3 , panel A is a photograph showing the behavior of SYNCRIP over-expressed in COS-7 cells by the indirect immunofluorescence technique using anti-SYNCRIP-N antibody stained. Panel B is a photograph showing the behavior of SYNCRIP over-expressed in COS-7 cells by indirect immunofluorescence technique using anti SYNCRIP-Pep antibody. - Further, mouse cerebellum was fractionated into a crude nuclear fraction, cytosol fraction, crude microsome fraction and crude synaptic vesicle fraction. Then, the localization of SYNCRIP in each of these fractions was examined. The results are shown in
FIG. 4 . - In the lanes in
FIG. 4 , P1 is a crude nuclear fraction from mouse cerebellum; S3 is a supernatant (cytosol) from nuclear fractionation; P3 is a crude microsome fraction containing vesicles; and P2′ is a crude synaptosome fraction. LP1 is a synaptic heavy membrane fraction obtained from synaptosomes lysed in a hypotonic solution; LP2 is a synaptic vesicle fraction; LS2 is a synaptic cytosol fraction; and PSD is a postsynaptic density fraction prepared from LP1 fraction. InFIG. 4 , the bands of IP3R Type I indicateinositol 1,4,5 triphosphate receptor I, and serve as a marker for crude microsome fraction. Further, the bands of PSD95 indicate postsynaptic density proteins, and serve as a marker for postsynaptic density fraction. - As seen from
FIG. 4 , while a SYNCRIP band appeared in the microsome fraction (P3), an hnRNP R band did not appear in the microsome fraction but appeared in the nuclear fraction (P1). Thus, it was demonstrated that these proteins are different in function and behavior. - (2) Time of Expression and Tissue Distribution of SYNCRIP
- The time of expression of SYNCRIP was determined by preparing cerebellum homogenates from
postnatal day FIG. 5 . InFIG. 5 , the bands in the upper panel indicate SYNCRIP, and the bands in the lower panel Syt-I. - As seen from
FIG. 5 , the expression of SYNCRIP in mouse cerebellum during the postnatal development was the highest at P7 (postnatal day 7) and decreased afterward (FIG. 5 ; upper panel). On the other hand, the expression of Syt-I gradually increased during the development (FIG. 5 ; lower panel). - Subsequently, tissues expressing SYNCRIP were determined by preparing homogenates (30 μg for each) from individual tissues of postnatal day 7 mice and performing Western blotting using anti-SYNCRIP-Pep antibody. The expression of hnRNP R in individual tissues was also determined. The results are shown in
FIG. 6 . InFIG. 6 , the bands pointed out by the upper arrow indicate hnRNP R (82 kDa), and the bands pointed out by the lower arrow SYNCRIP (66 kDa). - As seen from
FIG. 6 , the expression of SYNCRIP (66 kDa) was observed at an almost constant level not only in the central nervous tissues but also in all of the peripheral tissues tested (FIG. 6 ; lower arrow). The 82 kDa hnRNP R was expressed in parallel with SYNCRIP in various tissues (FIG. 6 ; upper arrow). - In order to examine whether the protein of the invention binds to RNA molecules or not, in vitro RNA binding assay was carried out.
- Briefly, [35S]-labeled SYNCRIP was prepared by in vitro translation using a TNT-coupled reticulocyte lysate system (Promega). An aliquot of [35S]-labeled SYNCRIP was incubated with an indicated amount of poly(A), poly(C) or poly(U) RNA or yeast tRNA in 50 μl of a binding buffer (10 mM Tris-HCl (pH 8.0), 1 mM EDTA and 10 mM NaCl) at 25° C. for 30 min. Then, 50 μl of poly(U)-Sephadex (20% slurry in the binding buffer) was added to each of the mixtures followed by incubation at 25° C. for 45 min. After washing the beads with 500 μl of the binding buffer 4 times, the bound fractions were subjected to 10% SDS-PAGE and analyzed by autoradiography.
- As shown in
FIG. 7 , [35S]-labeled SYNCRIP indeed bound to poly(U) RNA Sephadex. When poly(A) RNA is not contained in the sample (i.e., poly(A): 0), a strong band appears. When the amount of poly(A) RNA increases (i.e., poly(A): 10 and 50 μg), the band becomes weaker because the binding of the labeled SYNCRIP to the poly(U) RNA on carrier beads is inhibited, which results in liberation of SYNCRIP and its binding to poly(A) RNA (FIG. 7 ; the three lanes under poly(A) ). On the other hand, no changes in the intensity of bands were observed in yeast tRNA and poly(C) RNA. These substances did not compete with the poly(U) RNA on carrier beads for SYNCRIP binding. Thus, it was demonstrated that the protein of the invention, SYNCRIP, binds preferentially to poly(A) RNA. - In this Example, in vitro assay was performed to determine which region of SYNCRIP binds to the C2B domain of Synaptotagmin.
- (1) The Binding of Full-Length or Truncated SYNCRIP Expressed in COS-7 to GST-Syt-II C2B
- cDNA fragments encoding an N-terminal truncated SYNCRIP (ΔN; lacking amino acids 1-98 in the full-length amino acid sequence (SEQ ID NO: 4) ) (
FIG. 1B ) and a C-terminal truncated SYNCRIP (ΔC; lacking amino acids 401-561 in the full-length amino acid sequence (SEQ ID NO: 4) ) (FIG. 1B ), respectively, were transfected into COS-7 cells in the same manner as in Example 2. Using the thus obtained COS-7 cells and the COS-7 cells prepared in Example 2, the binding of the full-length or truncated SYNCRIP proteins to GST-Syt-II C2B was evaluated. - First, a cell lysate was prepared from each of the COS-7 cells expressing individual SYNCRIP proteins by suspending the cells in a cell lysis buffer of the following composition. Then, the cell lysate was centrifuged at 12,000 rpm at 4° C. for 20 min.
- Cell lysis buffer: 10 mM Hepes-NaOH (pH 7.4), 100 mM NaCl, 1 mM β-mercaptoethanol, 1 mM EDTA, 1% NP-40, 0.2 mM PMSF, 10 μM leupeptin, and 10 μM pepstatin A.
- Each lysate was incubated with an equal amount of GST-Sty-II C2B protein at 4° C. for 2 hr. Then, GST-Sty-II C2B protein-bound fractions were recovered with glutathione-Sepharose and examined by Western blotting using anti-SYNCRIP-Pep antibody. The antibody used in the Western blotting was prepared in Example 2. (In the subsequent Western blotting analyses, the antibodies used were also from Example 2.)
- (2) The Binding of Endogenous SYNCRIP from Mouse Brain to various GST-Syt-II Fusions and the Effect of Ca2+ and Mg2+ on the Binding
- Mouse whole brain detergent-extracts (2.5 mg/ml) were prepared in a lysis buffer of the following composition.
- Lysis buffer: 10 mM Hepes-NaOH (pH 7.4), 140 mM NaCl, 1% (w/v) Triton X-100, 1 mM β-mercaptoethanol, 1 mM EDTA, 0.2 mM PMSF, 10 μM leupeptin and 10 μM pepstatin A.
- To each 3 ml aliquot, EGTA (final concentration: 2 mM), CaCl2 (1 mM), EDTA (2 mM) or MgCl2 (1 mM) was added and incubated with 25 μg of a purified GST-fusion protein with a region of Syt-II or 25 μg of purified GST alone at 4° C. for 2 hr. After addition of 50 μl (50% slurry) of glutathione-Sepharose and another 1 hr incubation, the resins were extensively washed with an extraction buffer containing a chelating agent or divalent ion. The bound proteins were subjected to Western blotting using anti-SYNCRIP-N antibody to examine the binding of SYNCRIP to various regions of Syt-II.
- (3) The Binding of Full-Length SYNCRIP Expressed in Sf9 Cells to GST-CB2 from Various Syts
- For the expression of SYNCRIP in an insect cell Sf9, a cDNA fragment encoding full-length SYNCRIP was subcloned into pFASTBAC1 (Life Technology) to create a recombinant bacurovirus carrying SYNCRIP, which was then proliferated in accordance with the manufacturer's instructions. Sf9 cells cultured in TNM-FH medium supplemented with 10% fetal calf serum were infected with the proliferated recombinant virus. Forty-eight hours after the infection, the cells were used in binding experiments.
- A cell lysate containing the full-length SYNCRIP expressed in Sf9 cells was prepared in the same manner as described in (1) above. Each aliquot was incubated with 10-20 μg of one of GST fusion proteins with C2B domains from various Syts. The bound proteins were recovered and subjected to Western blotting using anti-SYNCRIP-N antibody to examine the binding of SYNCRIP to C2B domains from various Syts.
- (4) The Binding of Purified, His6-tagged C-Terminal Region of SYNCRIP to Purified GST Fusion Proteins with One of the Syt-II C2 Domains
- A His6-tagged recombinant protein comprising a C-terminal region of SYNCRIP (amino acids 401-561) was expressed in E. coli using pREST plasmid (Invitrogen). The recombinant protein was recovered from inclusion bodies by using a denaturing solution (6 M guanidine-HCl, 10 mM Tris-HCl (pH 8.0), 0.5 M NaCl, 1 mM β-mercapto-ethanol) and purified with ProBond resin. The denatured recombinant protein was refolded by dialysis against 10 mM Tris-HCl (pH 8.0), 10 mM β-mercaptoethanol, 0.1 M NaCl and 1 mM EDTA, with gradual decrease of urea concentration from 6 M to 0.001 M. The dialysate was centrifuged at 12,000 rpm at 4° C. for 20 min to remove the malfolded part and insoluble matter. After aliquots were incubated with various GST-fusion proteins with one of the Syt-II C2 domains, bound proteins were recovered and subjected to Western blotting using anti-Xpress antibody (Invitrogen).
- (5) Coimmunoprecipitation Experiments
- DNA fragments encoding Syt isoforms tagged with T7-epitope at the N-terminus were transiently transfected into COS cells separately. Forty-eight hours after the transfection, cells were harvested and suspended in a suspension buffer (10 mM Hepes-NaOH (pH 7.4), 100 mM NaCl, 0.5 mM β-mercaptoethanol, 1 mM EDTA, 1% NP-40, 0.2 mM PMSF, 10 μM leupeptin and 10 g M pepstatin). Lysates were prepared by centrifugation of the cell suspension at 12,000 rpm for 20 min and incubated with affinity purified anti-SYNCRIP-N antibody (3.5 μg antibody/1 ml lysate) at 4° C. for 2 hr, followed by another incubation with 10 μl (50% slurry) of protein G-Sepharose (Amersham Pharmacia Biotech) at 4° C. for 1 hr. After washing the beads with the suspension buffer 5 times, the resultant immunoprecipitates were subjected to Western blotting to examine the binding of SYNCRIP to T7-tagged Syt isoforms.
- (6) Results
- (i) SYNCRYP bound to GST-Syt-II C2B and to GST-Syt-II C2AB to an equal extent (
FIG. 9 ). However, SYNCRIP did not bind to GST-Sty-II C2A nor GST alone. This means that the protein of the invention binds to the C2B domain of Synaptotagmin. Further, the above-described binding was independent of Ca2+ and Mg2+. The evident binding in the presence of 1 mM MgCl2 that is close to the physiological concentration suggested possible similar binding in vivo. - (ii) Full-length (wild type: W), N-terminal truncated (ΔN) and C-terminal truncated (ΔC) SYNCRIP proteins were expressed in COS-7 cells to examine which region of SYNCRIP is important for its binding to Syt. All these constructs were confirmed as being expressed with expected sizes (
FIG. 8 ; see the band marked with “*” in each lane 1). Wild type and ΔN proteins bound to GST-Syt-II C2B as demonstrated by the appearance of a band at the same position as that of the band marked with “*” (FIG. 8 ; each lane 2). However, ΔC protein did not bind to GST-Syt-II C2B since no band appeared at the position corresponding to mark “*”. This result did not change even after reacting ΔC protein with GST-Syt-II C2B for a longer period. - (iii) The C-terminal region of SYBCRIP prepared in (4) above bound specifically to GST-Syt-II C2B, but did not bind to GST-Syt-II C2A nor GST alone (
FIG. 10 ). These results show that the C-terminal 161 amino acid region spanning frompositions 401 to 561 of full-length SYNCRIP (i.e., the amino acid sequence as shown in SEQ ID NO: 2 encoded by the nucleotide sequence of SEQ ID NO: 1) binds to the C2B domain of Syt. - In this Example, immunohistochemical studies were performed on postnatal day 7 mouse cerebellum in which the expression of SYNCRIP is highest during the postnatal development of mouse cerebellum, in order to examine whether SYNCRIP binds to Syt in vivo.
- A DNA fragment encoding SYNCRIP was transfected into COS-7 cells. Forty-eight hours after the transfection, the cells were washed with PBS twice and fixed with 4% paraformaldehyde in PBS at room temperature for 20 min. Fixed cells were permeabilized with 0.1% Triton X-100 in PBS for 5 min and immediately washed with
PBS 3 times. After blocking with 2% normal goat serum in PBS, cells were incubated with anti-SYNCRIP-N antibody (0.27 μg/ml) or anti-SYNCRIP-Pep antibody (0.55 μg/ml) in the blocking buffer at room temperature for 1 hr. After washing with PBS 5 times, the cells were incubated with FITC-conjugated goat anti-rabbit IgG (Vector, Burlingame, Calif.). For native tissues, postnatal day 7 ICR mice were perfused with 4% paraformaldehyde in PBS(−). The brains were excised and immersed in the same fixative for 2 hr, and then cryosectioned (8 μm thick). Each section was dried and rehydrated in PBS followed by immunoreaction. Immunofluorescence was observed using a Zeiss Axiophot epifluorescence microscope. The specificity of SYNCRIP immunoreactivity was confirmed by a parallel experiment using a pre-immune serum or anti-SYNCRIP antibody pre-incubated with an excessive amount of the antigenic polypeptide. - As a result, SYNCRIP was expressed in most neurons, i.e. granule cells in both external germinal layer and internal granular layer, and Purkinje cells (
FIG. 11 ). In the biochemical fractionation study described earlier, a significant amount of SYNCRIP was observed in LP2 fraction that is a representative synaptic vesicle-rich fraction morphologically (FIG. 4 ). However, where dendrites of Purkinje cells and synaptic structures concentrated and Syt-I signals were highly positive, anti-SYNCRIP-N antibody-reactive signals concentrated in perinuclear and somatic regions of granule cells and Purkinje cells, and were almost absent in the molecular layer without migrating granule cells therein (FIG. 11A , the region indicated as “ML”). - The parallel experiment with anti-SYNCRIP-Pep antibody showed that the immunoreactive signals were exclusively apparent in nuclei, suggesting that the perinuclear and somatic immunosignals with anti-SYNCRIP-N antibody indeed represented the SYNCRIP localization in neurons and that the SYNCRIP signals detected in LP2 fraction by the fractionation study might be derived from SYNCRIP on other membrane structure rather than synaptic vesicles.
- Since SYNCRIPT is expressed in every step of neurodevelopment and expressed ubiquitously in a wide variety of tissues, it is believed that the targets of SYNCRIP are not only the major Syt isoforms (Syt-I and Syt-II), but also other Syt isoforms. Then, the present inventor performed binding experiments between SYNCRIP and 11 Syt isoforms.
- Briefly, SYNCRIP was expressed in Sf9 cells (see Section (3) of Example 4). After preparation of a lysate from the cells, each aliquot was incubated with an almost equal volume of GST-Syt-C2B. The binding of SYNCRIP to GST-Syt-C2B was detected by immunoprecipitation using anti-SYNCRIP-N antibody.
- The results revealed that SYNCRIP binds to the C2B domains of Syt-III, -IV, -VII, -VIII, -IX and -XI in addition to Syt-I and -II (
FIG. 12 ). - The finding of ubiquitous tissue distribution of SYNCRIP (
FIG. 6 ) led the inventor to focus on ubiquitous isoforms of Syt as physiological targets of SYNCRIP. Thus, the inventor examined the interaction of SYNCRIP with ubiquitous isoforms of Syt in cells by immunoprecipitation. - Briefly, T7-epitope-tagged full-length Syt-IV, -V, -VII, -VIII and -IX were transiently expressed in COS-7 cells. Lysates were prepared from COS-7 cells and immunoprecipitated with anti-SYNCRIP-N antibody. The immunoprecipitates were examined by Western blotting with both anti-SYNCRIP-N antibody (
FIG. 13 ; middle panel) and anti-T7 antibody (FIG. 13 ; lower panel). The detection of T7-tagged Syt isoforms (Syt-IV, -VII, -VIII and -IX) by Western blotting with anti-T7 antibody confirmed that they were expressed at almost equal levels (FIG. 13 ; upper panel). The results of immunoblotting of the immunoprecipitates using anti-SYNCRIP-N antibody revealed that SYNCRIP is constantly expressed (FIG. 13 ; middle panel). The results of immunoblotting of the immunoprecipitates using anti-T7 antibody revealed that Syt-VII, -VIII and -IX were specifically coimmunoprecipitated with SYNCRIP (FIG. 13 ; lower panel). - Accordingly, it was demonstrated that the ubiquitous isoforms of Syt (i.e., Syt-VII, -VIII and -IX) are the target of SYNCRIP under physiological conditions.
- According to the present invention, RNA-binding proteins are provided. Since the protein of the invention is able to bind to Synaptotagmin on synaptic vesicles, the protein is useful as an agent for regulating neurotransmission.
-
- SEQ ID NO: 8: n represents a, g, c or t (location: 3).
- SEQ ID NO: 8: n represents a, g, c or t (location: 6).
- SEQ ID NO: 8: n represents a, g, c or t (location: 12).
- SEQ ID NO: 8: n represents a, g, c or t (location: 15).
- SEQ ID NO: 8: synthetic DNA
- SEQ ID NO: 9: n represents a, g, c or t (location: 10).
- SEQ ID NO: 9: synthetic DNA
Claims (31)
1. An isolated protein comprising an amino acid sequence selected from SEQ ID NO: 2.
2. An isolated protein selected from the group consisting of the following (a) and (b):
(a) a protein comprising the amino acid sequence as shown in SEQ ID NO: 4; or
(b) a protein which comprises the amino acid sequence as shown in SEQ ID NO: 4 having deletion, substitution or addition of one to ten amino acids within the region from position 1 to position 400 and which has RNA binding activity.
3. An isolated gene encoding the amino acid sequence as shown in SEQ ID NO: 2.
4. (canceled)
5. An isolated gene comprising a DNA selected from the group consisting of the following (a) and (b):
(a) a DNA consisting of the nucleotide sequence as shown in SEQ ID NO: 1; and
(b) a DNA which hybridizes to the nucleotide sequence as shown in SEQ ID NO: 1 under stringent conditions and which encodes a protein having RNA binding activity.
6. (canceled)
7. A recombinant vector comprising the gene according to claim 3 .
8. A transformant comprising the gene according to claim 3 .
9. A method of producing an RNA-binding protein comprising culturing the transformant according to claim 7 and recovering the RNA-binding protein from the resultant culture.
10. An antibody against the protein according to claim 1 .
11. A pharmaceutical composition for regulating neuronal functions, comprising the protein according to claim 1 .
12. A therapeutic agent for neurological diseases comprising the protein according to claim 1 as an active ingredient.
13. A pharmaceutical composition for regulating neuronal functions, comprising the gene according to claim 3 .
14. A therapeutic agent for neurological diseases, comprising the gene according to claim 3 .
15. A reagent for detecting a Synaptotagmin-binding and yet RNA-binding protein, comprising the antibody according to claim 10 .
16. A reagent for detecting Synaptotagmin, comprising the protein according to claim 1 .
17. A method of detecting an RNA-binding protein, comprising:
(a) franctioning a sample;
(b) reacting the resultant fractions with the antibody according to claim 10 which has been labeled; and
(c) detecting a signal from the resultant reaction products.
18. The method according to claim 17 , wherein the sample is a cell lysate or a cellular fraction thereof.
19. A method of detecting Synaptotagmin, comprising:
(a) fractionating a sample;
(b) reacting the resultant fractions with a protein an isolated protein comprising an amino acid sequence, which has been labeled, selected from the group consisting of SEQ. ID NO: 2, SEQ ID NO: 4; and SEQ ID NO: 4, that has deletion, substitution or addition of one to ten amino acids within the region from position 1 to position 400 and that has RNA binding activity.
which has been labeled;
(c) reacting the reaction products obtained in step (b) with the antibody according to claim 10 which has been labeled; and
(d) detecting a signal from the reaction products obtained in step (c) above.
20. The method of claim 19 , wherein the sample is a cell lysate or a cellular fraction thereof, or a cell lysate containing a fusion protein composed of Synaptotagmin and glutathione-S-transferase.
21. A recombinant vector comprising the gene according to claim 5 .
22. An antibody against the protein according to claim 2 .
23. A pharmaceutical composition for regulating neuronal functions, comprising the protein according to claim 2 .
24. A therapeutic agent for neurological diseases comprising the protein according to claim 2 as an active ingredient.
25. A pharmaceutical composition for regulating neuronal functions, comprising the gene according to claim 5 .
26. A therapeutic agent for neurological diseases, comprising the gene according to claim 5 .
27. A reagent for detecting Synaptotagmin, comprising the protein according to claim 2 .
28. A reagent for detecting Synaptotagmin, comprising the protein according to claim 10 .
29. A reagent for detecting Synaptotagmin, comprising the antibody according to claim 10 .
30. A method of detecting Synaptotagmin, comprising:
(a) fractionating a sample;
(b) reacting the resultant fractions with a protein comprising an amino acid sequence, which has been labeled, selected from the group consisting of SEQ. ID NO: 2, SEQ ID NO: 4, and SEQ ID NO: 4 that has deletion, substitution or addition of one to ten amino acids within the region from position 1 to position 400 and that has RNA binding activity;
(c) reacting the reaction products obtained in step (b) with the antibody according to claim 10 which has been labeled; and
(d) detecting a signal from the reaction products obtained in step (c) above.
31. A transformant comprising the gene according to claim 5.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/943,015 US20060019261A1 (en) | 2000-09-29 | 2004-09-17 | RNA-binding protein |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000299812A JP2002101890A (en) | 2000-09-29 | 2000-09-29 | Rna-binding protein |
JP2000-299812 | 2000-09-29 | ||
US09/821,687 US6794500B2 (en) | 2000-09-29 | 2001-03-30 | RNA-binding protein |
US10/943,015 US20060019261A1 (en) | 2000-09-29 | 2004-09-17 | RNA-binding protein |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/821,687 Division US6794500B2 (en) | 2000-09-29 | 2001-03-30 | RNA-binding protein |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060019261A1 true US20060019261A1 (en) | 2006-01-26 |
Family
ID=18781574
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/821,687 Expired - Fee Related US6794500B2 (en) | 2000-09-29 | 2001-03-30 | RNA-binding protein |
US10/943,015 Abandoned US20060019261A1 (en) | 2000-09-29 | 2004-09-17 | RNA-binding protein |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/821,687 Expired - Fee Related US6794500B2 (en) | 2000-09-29 | 2001-03-30 | RNA-binding protein |
Country Status (3)
Country | Link |
---|---|
US (2) | US6794500B2 (en) |
JP (1) | JP2002101890A (en) |
CA (1) | CA2340303A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10164556A1 (en) * | 2001-12-14 | 2003-07-03 | Medinnova Ges Med Innovationen | Test system for the search or testing of active substances that influence the growth and / or survival of nerve cells |
WO2018017144A1 (en) | 2016-07-19 | 2018-01-25 | Brandeis University | Compositions and methods for identifying rna binding polypeptide targets |
US11920195B2 (en) * | 2020-06-25 | 2024-03-05 | Korea Institute Of Science And Technology | Method for diagnosing drug addiction, method for screening therapeutic agent for drug addiction and pharmaceutical composition for preventing or treating drug addiction |
-
2000
- 2000-09-29 JP JP2000299812A patent/JP2002101890A/en active Pending
-
2001
- 2001-03-30 CA CA002340303A patent/CA2340303A1/en not_active Abandoned
- 2001-03-30 US US09/821,687 patent/US6794500B2/en not_active Expired - Fee Related
-
2004
- 2004-09-17 US US10/943,015 patent/US20060019261A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US6794500B2 (en) | 2004-09-21 |
US20020106724A1 (en) | 2002-08-08 |
JP2002101890A (en) | 2002-04-09 |
CA2340303A1 (en) | 2002-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5928884A (en) | FHIT proteins and nucleic acids and methods based thereon | |
US5962652A (en) | Antibodies to protein, FAF1 | |
US20070117166A1 (en) | Use of ULIP proteins in the diagnosis and therapy of cancers and paraneoplastic neurological syndromes | |
JP2007330258A (en) | Binding domains in Notch and Delta proteins | |
SK6222001A3 (en) | Nogo protein, its purified fragment, chimeric protein and purified molecule with its content, isolated nucleic acid, vector containing same, recombinant cell, method for producing recombinant protein and use thereof | |
JPH09507744A (en) | A novel fission phosphoprotein: mitocin | |
US6077686A (en) | Shc proteins | |
US20020054870A1 (en) | Peptide from soluble form of acetylcholinesterase, active as a calcium channel modulator | |
WO1997032020A9 (en) | Shc proteins | |
US20060228365A1 (en) | Protein and gene involved in myocyte differentiation | |
JPH09505730A (en) | Methods and compositions for treating BCR-ABL associated leukemia and other cell proliferative disorders | |
US6794500B2 (en) | RNA-binding protein | |
US5580955A (en) | Fragments of neurofibromin (NF1) and method to reverse activated ras induced malignant transformation in mammalian cells | |
US7544481B1 (en) | Nucleic acids encoding CD40 binding protein | |
JP2001516586A (en) | DNA encoding RAS carboxyl-terminal processing protein | |
US20050069557A1 (en) | Vertebrate globin | |
US6013495A (en) | Methods of use for integrin B1C cell growth inhibitor | |
US20040234526A1 (en) | Use of a compound antagonist of esm-1 protein for producing a medicine for treating cancer | |
US5955354A (en) | RAS P21-interacting protein (RGL) and its RAS interacting domain (RID) | |
JPH10508761A (en) | Novel PKA binding proteins and uses thereof | |
US5962261A (en) | Polynucleotides encoding a neuronal extracellular matrix protein | |
AU1614400A (en) | Human glycine transporter type 2 | |
US6747138B1 (en) | Methods and compositions for regulating Fas-associated apoptosis | |
JP2002503466A (en) | Retinoblastoma protein complex and retinoblastoma interacting protein | |
US5741890A (en) | Protein binding fragments of gravin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |